[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 247
1. Aziz F: Radiological Findings in a case of Advance staged Mesothelioma. J Thorac Dis; 2009 Dec;1(1):46-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • But computed tomography (CT) is the imaging technique of choice for charactering pleural masses.
  • Certain CT features help differentiate benign from malignant processes.
  • This short article highlights the salient CT appearance of mesothelioma; the most common pleural tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22263002.001).
  • [ISSN] 2072-1439
  • [Journal-full-title] Journal of thoracic disease
  • [ISO-abbreviation] J Thorac Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC3256484
  • [Keywords] NOTNLM ; Advance staged Mesothelioma / Radiological Findings
  •  go-up   go-down


2. Carretta A, Bandiera A, Melloni G, Ciriaco P, Arrigoni G, Rizzo N, Negri G, Zannini P: Solitary fibrous tumors of the pleura: Immunohistochemical analysis and evaluation of prognostic factors after surgical treatment. J Surg Oncol; 2006 Jul 1;94(1):40-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the pleura: Immunohistochemical analysis and evaluation of prognostic factors after surgical treatment.
  • BACKGROUND AND OBJECTIVES: Solitary fibrous tumors of the pleura (SFTP) are rare neoplasms with unusual histological and clinical features.
  • Although surgery is the treatment of choice for SFTP, tumor recurrence may occur after complete resection, even in tumors with benign histological features.
  • Mean tumor size was 10 cm.
  • Histological features were benign in 16 patients and malignant in 2.
  • A higher incidence of tumor recurrence was observed when SFTP originated from the parietal pleura, had malignant histological features and a lower expression of progesterone receptors (P < 0.05).
  • [MeSH-major] Fibroma / pathology. Fibroma / surgery. Neoplasm Recurrence, Local / pathology. Pleural Neoplasms / pathology. Pleural Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788942.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


3. Chiosea S, Krasinskas A, Cagle PT, Mitchell KA, Zander DS, Dacic S: Diagnostic importance of 9p21 homozygous deletion in malignant mesotheliomas. Mod Pathol; 2008 Jun;21(6):742-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Definitive diagnosis of malignant mesothelioma in small specimens can be extremely difficult based on morphology alone.
  • Recent studies demonstrated that this alteration may be useful for differentiating benign from malignant mesothelial proliferations in cytology specimens.
  • FISH analysis demonstrated homozygous deletion of the 9p21 locus in 35 of 52 cases (67%) of pleural mesothelioma and in 5 of 20 cases of peritoneal mesothelioma (25%) (P<0.005).
  • None of 40 cases of reactive pleural mesothelial proliferations showed p16 deletion (P<0.005).
  • Loss of immunoexpression of p16 was observed in 71% of the peritoneal mesotheliomas, 40% of the pleural malignant mesotheliomas and 15% of the reactive mesothelial cells.
  • [MeSH-major] Gene Deletion. Genes, p16. Mesothelioma / genetics. Peritoneal Neoplasms / genetics. Pleural Neoplasms / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18327208.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


Advertisement
4. Ramírez GA, Spattini G, Altimira J, García B, Vilafranca M: Clinical and histopathological features of a thymolipoma in a dog. J Vet Diagn Invest; 2008 May;20(3):360-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study presents a case of a canine thymolipoma, which is a rare, slow-growing, benign tumor of the thymus composed of mature adipose tissue and thymic tissue.
  • Radiology revealed pleural effusion and a mediastinal mass with a fatty appearance.
  • To the authors' knowledge, this is the first description of this uncommon neoplasm in a dog.
  • The possible histogenesis for this neoplasia in a dog is also discussed.
  • [MeSH-major] Dog Diseases / diagnosis. Lipoma / veterinary. Thymus Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460628.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Minato H, Nojima T, Kurose N, Kinoshita E: Adenomatoid tumor of the pleura. Pathol Int; 2009 Aug;59(8):567-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the pleura.
  • A case of adenomatoid tumor of the pleura is reported, and its differential diagnosis from benign and malignant pleural lesions is discussed.
  • A small pleural nodule was incidentally found during a thoracic operation in a 54-year-old woman with esophageal cancer.
  • A 7 mm, circumscribed tumor had characteristic features of adenomatoid tumor.
  • The tumor was composed of an aggregation of irregularly shaped tubulocystic spaces with fibrous stoma.
  • On immunohistochemistry the tumor cells were positive for AE1/AE3, CAM5.2, vimentin, cytokeratin 5/6, D2-40, calretinin, thrombomodulin, and WT-1, but negative for CEA, Leu M1 (CD15), thyroid transcription factor-1, epithelial membrane antigen, desmin, glucose transporter-1 (GLUT-1), CD31, and CD34.
  • Adenomatoid tumor of the pleura is rare, and the pathogenesis has not been elucidated.
  • Recognition of these benign mesothelial lesions in the pleura is important to avoid misdiagnosis.
  • [MeSH-major] Adenomatoid Tumor / pathology. Neoplasms, Multiple Primary / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Dermatomyositis / complications. Esophageal Neoplasms / complications. Esophageal Neoplasms / pathology. Female. Humans. Immunohistochemistry. Incidental Findings. Liver Cirrhosis, Biliary / complications. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19627540.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


6. Ghayumi SM, Mehrabi S, Doroudchi M, Ghaderi A: Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients. Pathol Oncol Res; 2005;11(4):236-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of tumor markers for differentiating malignant and benign pleural effusions of Iranian patients.
  • In order to evaluate the diagnostic yield of tumor markers in differentiating malignant and benign pleural effusions, we carried out a prospective study in a group of Iranian people.
  • Pleural and serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen 15-3 (CA 15-3), neuron-specific enolase (NSE) and cancer antigen 125 (CA 125) were assayed prospectively in patients with pleural effusion (40 malignant and 37 benign).
  • The highest sensitivity was obtained with a combination of CA 15-3 in serum, and CA 15-3 and CEA in pleural fluid (80%), also with combination of CA 15-3 in serum, and CA 15-3, NSE and CEA in pleural fluid (80%).
  • The highest specificity was obtained with combination of CA 15-3 in serum, and CA 15-3 and NSE in pleural fluid (100%), and also with combination of CA 15-3 in serum, and CA15-3, NSE and CEA in pleural fluid (100%).
  • [MeSH-major] Biomarkers, Tumor / analysis. Cell Differentiation. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Clin (Barc). 1993 Jul 3;101(6):237-8 [8332026.001]
  • [Cites] Eur Respir J. 1996 Jan;9(1):17-23 [8834328.001]
  • [Cites] Thorax. 2003 May;58 Suppl 2:ii8-17 [12728146.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):736-40 [8756365.001]
  • [Cites] Am J Med. 1977 Nov;63(5):695-702 [930945.001]
  • [Cites] Mayo Clin Proc. 1985 Mar;60(3):158-64 [3974296.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Sep;21(9):1083-7 [3905413.001]
  • [Cites] Respirology. 2003 Dec;8(4):487-91 [14629653.001]
  • [Cites] Am J Surg. 1995 Jul;170(1):69-74 [7793501.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):9-16 [11162861.001]
  • [Cites] Acta Cytol. 1979 Nov-Dec;23(6):443-8 [295160.001]
  • [Cites] Lung Cancer. 2002 Apr;36(1):83-9 [11891038.001]
  • [Cites] Chest. 2004 Dec;126(6):1757-63 [15596670.001]
  • [Cites] Chest. 1980 Oct;78(4):587-90 [7418482.001]
  • [Cites] Eur Respir J. 1988 Apr;1(4):341-4 [3165069.001]
  • [Cites] Chest. 2004 Dec;126(6):1721-2 [15596661.001]
  • [Cites] Chest. 1995 Jun;107(6):1598-603 [7781353.001]
  • [Cites] Cancer. 1999 Oct 15;86(8):1488-95 [10526277.001]
  • [Cites] Chest. 1997 Mar;111(3):643-7 [9118701.001]
  • [Cites] Arch Pathol Lab Med. 1992 Jun;116(6):626-31 [1616424.001]
  • [Cites] Lung. 1994;172(3):183-4 [8201832.001]
  • [Cites] Clin Chim Acta. 2000 Oct;300(1-2):43-55 [10958862.001]
  • [Cites] Med Clin (Barc). 1986 Mar 22;86(11):439-43 [2423819.001]
  • [Cites] Chest. 1985 Mar;87(3):351-5 [3971760.001]
  • (PMID = 16388321.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / Mucin-1; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


7. Brauner M, Brillet PY: [Other malignant tumors of the pleura]. Rev Pneumol Clin; 2006 Apr;62(2):124-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Other malignant tumors of the pleura].
  • Malignant tumors of the pleura are most often diffuse, nethertheless they are sometimes localized.
  • There is an overlap of the radiologic features of the benign and malignant pleural lesions.
  • The differential diagnosis may be difficult, even on histological sample.
  • Imaging allows the diagnosis of pleural involvement, suggests the malignity, guides percutaneous or thoracoscopic biopsies of the pleura, defines extent of the tumor and follows the course of the disease.
  • We will describe the malignant pleural tumors: pleural metastases, pleural involvement of broncho-pulmonary cancer, of lymphoma and leukaemia.
  • Then the rare pleural tumors will be described: malignant pleural fibroma, sarcoma, histiocytoma and hemangiopericytoma.
  • [MeSH-major] Pleural Neoplasms / pathology. Pleural Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16670666.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 12
  •  go-up   go-down


8. Wu M, Yuan S, Szporn AH, Gan L, Shtilbans V, Burstein DE: Immunocytochemical detection of XIAP in body cavity effusions and washes. Mod Pathol; 2005 Dec;18(12):1618-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We performed an immunocytochemical survey of XIAP expression in cell blocks from benign and malignant body cavity effusions and washes.
  • In all, 116 alcohol-fixed, formalin postfixed paraffin-embedded cell block specimens from 82 pleural effusions, 22 ascites, 11 pelvic/peritoneal washes and one pericardial effusion were evaluated immunocytochemically with monoclonal anti-XIAP (#610763, BD Biosciences, San Jose, USA) 1:250, 4 degrees C x 72 h, and developed using EnVision-Plus reagents (Dako) and diaminobenzidine as chromagen.
  • Benign effusions (n = 35) were virtually XIAP-negative except for two cases (6%) in which histiocytes showed moderate staining.
  • XIAP immunostaining, when strong, allows for ready distinction of malignant from benign and reactive cell populations.
  • The degree of XIAP staining of tumor cells may be a means of identifying the most therapy-resistant cases (ie, those with strong XIAP expression), and allow additional triaging to XIAP-blocking drugs presently being developed and clinically tested.
  • [MeSH-major] Ascitic Fluid / chemistry. Biomarkers, Tumor / analysis. Immunoenzyme Techniques / methods. Peritoneal Lavage. Pleural Effusion, Malignant / chemistry. X-Linked Inhibitor of Apoptosis Protein / analysis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16118627.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / X-Linked Inhibitor of Apoptosis Protein
  •  go-up   go-down


9. Li G, Passebosc-Faure K, Feng G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: MN/CA9: a potential gene marker for detection of malignant cells in effusions. Biomarkers; 2007 Mar-Apr;12(2):214-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The presence of malignant cells in effusions has implications in diagnosis, tumour staging and prognosis.
  • The present study was to evaluate MN/CA9 as a new molecular marker for the detection of cancer cells in pleural effusions.
  • Seventy-one pleural effusions including 59 malignant effusions from patients with cancer, and 12 patients with benign diseases as a control, were subjected to RT-PCR for detection of MN/CA9 gene expression.
  • MN/CA9 gene expression was detected in 53/59 (89.8%) pleural effusions from cancer patients (15/16 for breast cancers, 10/11 for lung cancers, 4/4 for ovary cancers, 2/3 for colon-rectal cancers, 5/6 for cancers of unknown site, 7/8 for mesothelioma and 10/11 for other cancers).
  • [MeSH-major] Antigens, Neoplasm / analysis. Carbonic Anhydrases / analysis. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Case-Control Studies. Gene Expression. Humans. Neoplasm Proteins / analysis. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536770.001).
  • [ISSN] 1354-750X
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


10. Iwata T, Yasuoka T, Hanada S, Suehiro Y, Nishibayashi A, Inoue K, Kobayashi Y, Mizoguchi H, Miura T: Inverted intercostal hernia of soft tissue manifested as slow-growing chest wall tumor after thoracotomy. Ann Thorac Surg; 2010 Oct;90(4):1355-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inverted intercostal hernia of soft tissue manifested as slow-growing chest wall tumor after thoracotomy.
  • An 80-year-old woman had an asymptomatic chest wall tumor.
  • She had undergone thoracotomy to treat a benign lesion 11 years previously.
  • Therefore, we thought that the soft tissue of the back was drawn into the pleural cavity through the widened intercostal space during the previous thoracotomy.
  • [MeSH-major] Diagnostic Errors. Hernia / diagnosis. Soft Tissue Neoplasms / diagnosis. Thoracotomy / adverse effects

  • MedlinePlus Health Information. consumer health - Hernia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20868847.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Lee JH, Chang JH: Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest; 2005 Oct;128(4):2298-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer.
  • MEASUREMENTS AND RESULTS: Levels of CEA, NSE, and CYFRA 21-1 were measured by immunoassay in the serum and pleural fluid of patients with lung cancer and of patients with tuberculous pleurisy.
  • Patients with lung cancer were found to have significantly higher serum and pleural fluid levels of CEA and CYFRA 21-1 than patients with tuberculous pleurisy.
  • Using cutoff values of 5 ng/mL, 20 ng/mL, and 3.3 ng/mL for serum CEA, NSE, and CYFRA 21-1, respectively, the sensitivities and specificities of these tumor markers were as follows for differentiating malignant effusion from benign: CEA, 68% and 93%; NSE, 34% and 93%; and CYFRA 21-1, 45% and 100%.
  • Using cutoff values of 5 ng/mL, 20 ng/mL, and 45 ng/mL for pleural fluid, the sensitivities and specificities were as follows: CEA, 82% and 94%; NSE, 36% and 94%; and CYFRA 21-1, 61% and 81%.
  • A combination of pleural fluid CEA and NSE increased sensitivity and specificity.
  • CONCLUSIONS: In the diagnosis of malignant effusion associated with lung cancer, the determinations of CEA and NSE in pleural fluid could enhance diagnostic yield better than those of all three tumor markers.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Keratins / blood. Lung Neoplasms / diagnosis. Phosphopyruvate Hydratase / analysis
  • [MeSH-minor] Antigens, Neoplasm / analysis. Antigens, Neoplasm / blood. Biomarkers, Tumor / blood. Case-Control Studies. Humans. Keratin-19. Peptide Fragments / analysis. Pleural Effusion. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16236887.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Peptide Fragments; 0 / antigen CYFRA21.1; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


12. Chen ML, Chang JH, Yeh KT, Chang YS, Chang JG: Epigenetic changes in tumor suppressor genes, P15, P16, APC-3 and E-cadherin in body fluid. Kaohsiung J Med Sci; 2007 Oct;23(10):498-503
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epigenetic changes in tumor suppressor genes, P15, P16, APC-3 and E-cadherin in body fluid.
  • The inactivation of tumor suppressor genes by promoter methylation plays an important role in the development of cancers; it can also be used as a marker to distinguish cancerous cells from non-cancer cells.
  • In this study, we investigated the aberrant methylation profile of the tumor suppressor genes P15, P16, APC and E-cadherin in the cells of body fluid.
  • From these results, we suggest that methylation-specific polymerase chain reaction to analyze the promoters of tumor suppressor genes can distinguish between malignant effusion and benign effusion, and may help cytologists to make more accurate diagnoses.
  • [MeSH-major] Ascitic Fluid / metabolism. Cadherins / genetics. Cyclin-Dependent Kinase Inhibitor p15 / genetics. Epigenesis, Genetic. Genes, APC. Genes, Tumor Suppressor. Genes, p16. Pleural Effusion / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055295.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Cadherins; 0 / Cyclin-Dependent Kinase Inhibitor p15
  •  go-up   go-down


13. Munteanu M, Petrescu F, Pleşea E, Stanciu E, Enache SD, Munteanu MC, Munteanu AC, Pîrşcoveanu M, Stoica Z, Gugilă I: [Pseudo-Meigs syndrome, a rare variant]. Chirurgia (Bucur); 2006 Mar-Apr;101(2):205-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Variantă rară de sindrom pseudo-Meigs.
  • The pseudo- Meigs syndrome is defined as a pelvic tumour, other than the ovarian fibroma complicated with ascites and hydrothorax that can be recovered after the tumour is surgically extirpated.
  • She was sent to the ER because she had severe respiratory insufficiency, arterial high blood pressure, tachycardia and, at the clinical examination, she presented massive right hydrothorax, ascites, and pelvic tumour.
  • The biologic explorations (the benign cytology in the pleural liquid and ascites, CA-125 with ten times the normal value) and the imagery completed the picture of a Meigs/ pseudo-Meigs syndrome that implied the laparotomy.
  • The H-P examination and the postoperative evolution confirmed the diagnosis.
  • We presented this case in order to emphasize both its rarity and its real positive and differential diagnosis problems.
  • [MeSH-major] Leiomyoma / diagnosis. Meigs Syndrome / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Ascites / etiology. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Diagnosis, Differential. Female. Humans. Hydrothorax / etiology. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16752689.001).
  • [ISSN] 1221-9118
  • [Journal-full-title] Chirurgia (Bucharest, Romania : 1990)
  • [ISO-abbreviation] Chirurgia (Bucur)
  • [Language] rum
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


14. Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ: Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer; 2008 May 6;98(9):1562-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MUC1 mRNA expression was significantly higher in mesothelioma samples than in benign mesothelial cells.
  • CA15.3 (soluble MUC1) levels were significantly higher in the serum of mesothelioma patients than in healthy controls but were not significantly different to levels in patients with benign asbestos-related disease.
  • CA15-3 in effusions could differentiate malignant from benign effusions but were not specific for mesothelioma.
  • Thus, as in other cancers, alterations in MUC1 biology occur in mesothelioma and these results suggest that specific MUC1 characteristics may be useful for mesothelioma diagnosis and should also be investigated as a potential therapeutic target.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Mesothelioma / diagnosis. Mesothelioma / metabolism. Mucin-1 / metabolism. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Nov;81(6):1059-65 [10576665.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5129-35 [16951230.001]
  • [Cites] Cytopathology. 2000 Jun;11(3):139-51 [10877273.001]
  • [Cites] Blood. 2000 Nov 1;96(9):3102-8 [11049990.001]
  • [Cites] Lung Cancer. 2001 Jan;31(1):9-16 [11162861.001]
  • [Cites] Curr Opin Mol Ther. 2001 Feb;3(1):102-5 [11249725.001]
  • [Cites] Int J Cancer. 2002 Jul 10;100(2):166-71 [12115565.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2002 Apr;7(2):209-21 [12463741.001]
  • [Cites] Clin Breast Cancer. 2003 Feb;3 Suppl 4:S134-8 [12620150.001]
  • [Cites] Lung Cancer. 2003 Jun;40(3):289-94 [12781427.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Histopathology. 2004 Feb;44(2):147-55 [14764058.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(2):189-231 [15270554.001]
  • [Cites] Arch Pathol Lab Med. 2004 Oct;128(10):1131-5 [15387710.001]
  • [Cites] Ann Intern Med. 1972 Oct;77(4):507-13 [4642731.001]
  • [Cites] Br J Cancer. 1985 Sep;52(3):347-54 [3899155.001]
  • [Cites] Cancer Res. 1993 Feb 15;53(4):755-61 [7679050.001]
  • [Cites] Cancer Res. 1995 Dec 1;55(23 Suppl):5847s-5851s [7493358.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:88-99 [9422093.001]
  • [Cites] Tumour Biol. 1998;19 Suppl 1:111-7 [9422095.001]
  • [Cites] Cancer. 1998 Feb 1;82(3):583-90 [9452278.001]
  • [Cites] Diagn Cytopathol. 2005 Mar;32(3):156-9 [15690334.001]
  • [Cites] Lancet. 2005 Jul 30-Aug 5;366(9483):397-408 [16054941.001]
  • [Cites] Oncologist. 2005 Aug;10(7):501-7 [16079317.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):405-11 [16052519.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jan;55(1):63-7 [15864588.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):869-77 [16467101.001]
  • [Cites] Cancer Res. 2006 Jun 1;66(11):5910-8 [16740731.001]
  • [Cites] J Urol. 2006 Jul;176(1):91-5 [16753376.001]
  • [Cites] Tumour Biol. 2000 Jul-Aug;21(4):197-210 [10867613.001]
  • (PMID = 18454162.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / Mucin-1; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2391110
  •  go-up   go-down


15. Yasumitsu A, Tabata C, Tabata R, Hirayama N, Murakami A, Yamada S, Terada T, Iida S, Tamura K, Fukuoka K, Kuribayashi K, Nakano T: Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma. J Thorac Oncol; 2010 Apr;5(4):479-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
  • INTRODUCTION: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor of mesothelial origin associated with asbestos exposure.
  • METHODS: Serum concentrations of VEGF were measured in 51 patients with MPM and 42 individuals with benign asbestos-related diseases (asbestosis or pleural plaques) or who were healthy despite asbestos exposure.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Mesothelioma / blood. Pleural Neoplasms / blood. Vascular Endothelial Growth Factor A / blood
  • [MeSH-minor] Aged. Asbestos / adverse effects. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Neoplasm Staging. Occupational Exposure. Prognosis. ROC Curve. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Thorac Oncol. 2011 May;6(5):971-2 [21623273.001]
  • (PMID = 20357617.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 1332-21-4 / Asbestos
  •  go-up   go-down


16. Dejmek A: CK5/6 in effusions: no difference between mesothelioma and pulmonary and nonpulmonary adenocarcinoma. Acta Cytol; 2008 Sep-Oct;52(5):579-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To test the performance of CK5/6 for the differentiation between mesothelioma, adenocarcinoma and benign mesothelia/proliferations in effusion cytology.
  • STUDY DESIGN: CKS/6 immunocytochemistry was applied to ethanol-fixed cytospin preparations from 74 benign and malignant effusions.
  • RESULTS: Reactivity was seen in 7 of 8 mesotheliomas and in 9 of 11 benign mesothelial proliferations but also in 11 of l7 pulmonary adenocarcinomas and in 12 of 31 adenocarcinomas of nonpulmonary origin.
  • The high reactivity rate in pulmonary adenocarcinomas disagrees with the results obtained with histologic sections from solid tumor tissue, and CK5/6 seems to be of very limited value as an additional marker in effusion cytology.
  • [MeSH-major] Adenocarcinoma / metabolism. Carcinoma, Squamous Cell / metabolism. Keratin-5 / metabolism. Keratin-6 / metabolism. Lung Neoplasms / metabolism. Mesothelioma / metabolism. Pleural Effusion / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18833821.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-5; 0 / Keratin-6
  •  go-up   go-down


17. Zhang KH, Cao F, Fu QB, Zhu JQ, Chen J, Lv NH: Detection of mRNAs of GA733 genes by RT-PCR in exfoliated cells of pleural and peritoneal effusions and its clinical values. Intern Med; 2007;46(18):1489-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of mRNAs of GA733 genes by RT-PCR in exfoliated cells of pleural and peritoneal effusions and its clinical values.
  • OBJECTIVE: To evaluate the diagnostic values of the detection of mRNAs of GA733 gene family in exfoliated cells of pleural and peritoneal effusions.
  • METHODS: Sixty specimens of pleural and peritoneal fluids from 60 patients were collected.
  • Patients Sixty patients with pleural or peritoneal effusions, from May 2003 and August 2004, aged 23-85 (average 56.5 years).
  • RESULTS: GA733-1 and GA733-2 mRNA were positive in 5 (13.9%) and 27 (75.0%) of 36 malignant specimens, and in 1 and 7 of 11 cause-unknown specimens, respectively, but both of them were negative in all 13 benign specimens, and the difference of GA733-2 mRNA positive rates among the three groups was significant (P<0.005), but that of GA733-1 mRNA was not (P>0.05).
  • Sensitivity, specificity and accuracy of detection for GA733-2 mRNA for diagnosis of malignant effusions were 75.0%, 100% and 81.6%, respectively.
  • CONCLUSIONS: The detection of GA733-2 mRNA by qualitative RT-PCR is sensitive and highly specific for the diagnosis of malignant pleural and peritoneal effusions, while the diagnostic value of GA733-1 mRNA needs to be further investigated.
  • [MeSH-major] Antigens, Neoplasm / genetics. Ascitic Fluid / metabolism. Ascitic Fluid / pathology. Biomarkers, Tumor / genetics. Cell Adhesion Molecules / genetics. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / genetics. RNA, Messenger / isolation & purification. Reverse Transcriptase Polymerase Chain Reaction / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17878632.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / RNA, Messenger; 0 / tumor-associated antigen GA733
  •  go-up   go-down


18. Toporcer T, Belák J, Böör A, Kudlác M, Lakyová L, Radonak J: [Giant solitary fibrous tumor of the pleura--case report]. Rozhl Chir; 2009 Mar;88(3):97-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant solitary fibrous tumor of the pleura--case report].
  • [Transliterated title] Obrovský solitárny fibrózny tumor pleury--kazuistika.
  • Solitary fibrous tumors of the pleura are rare malignant pathological findings, accounting for only 5% of all pleural neoplasms.
  • The authors performed right-sided thoracotomy and removed an encapsulated solid tumor measuring 24 x 16 x 13.5 cm and weighting 2850 grams from the thoracic cavity.
  • Benign solitary fibrous tumor was diagnosed on histology.
  • The postoperative course was complicated by bleeding into the pleural cavity, which was managed conservatively and did not require subsequent surgical revision.
  • The aim of the study is to draw attention to this tumorous disorder of the pleura - the solitary fibrous tumor.
  • [MeSH-major] Pleural Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19526938.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] slo
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


19. Shen J, Pinkus GS, Deshpande V, Cibas ES: Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids. Am J Clin Pathol; 2009 Apr;131(4):516-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
  • We compared the effectiveness of epithelial membrane antigen (EMA) with 2 newly described markers, X-linked inhibitor of apoptosis protein (XIAP) and an isoform of glucose transporter (GLUT-1), in the distinction between malignant mesothelioma (MM) and benign effusion (BE) in body cavity fluids.
  • Based on these findings, EMA is a better marker than XIAP or GLUT-1 for the diagnosis of MM.
  • [MeSH-major] Glucose Transporter Type 1 / biosynthesis. Mesothelioma / diagnosis. Mucin-1 / biosynthesis. Pleural Effusion, Malignant / diagnosis. Pleural Neoplasms / diagnosis. X-Linked Inhibitor of Apoptosis Protein / biosynthesis
  • [MeSH-minor] Aged. Aged, 80 and over. Area Under Curve. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19289587.001).
  • [ISSN] 1943-7722
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Mucin-1; 0 / X-Linked Inhibitor of Apoptosis Protein; 0 / XIAP protein, human
  •  go-up   go-down


20. Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L: Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J Nucl Med; 2007 Sep;48(9):1442-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor-to-normal tissue tracer values for both (99m)Tc-octreotide and (18)F-FDG were determined using region of interests and expressed as T/N(r) and T/N(m), respectively.
  • Final diagnosis was confirmed by histopathologic analysis or clinical follow-up.
  • Thirteen of the 44 patients had benign lung lesions.
  • Thirteen patients with 39 distant sites of abnormal uptake visualized (imaging stage IV) with (99m)Tc-octreotide included 2 patients with brain metastases, 6 patients with pleural invasion and multiple bone metastasis, 2 patients with contralateral internal lung metastasis and pleural invasion, and 3 patients with only multiple bone metastasis.
  • The final diagnosis was confirmed by histopathology or clinical follow-up.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704242.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; RWM8CCW8GP / Octreotide
  •  go-up   go-down


21. Radjenovic-Petkovic T, Pejcic T, Nastasijević-Borovac D, Rancic M, Radojkovic D, Radojkovic M, Djordjevic I: Diagnostic value of CEA in pleural fluid for differential diagnosis of benign and malign pleural effusion. Med Arh; 2009;63(3):141-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of CEA in pleural fluid for differential diagnosis of benign and malign pleural effusion.
  • The diagnostic value of tumor markers in pleural fluid is still the subject of debate.
  • The aim of this work was to evaluate diagnostic value of carcinoembryonic antigen (CEA) in pleural fluid for differentiating malignant from non malign pleural effusion, and their additive value to cytological examination.
  • PATIENTS: Eighty two patients with pleural effusion, forty one with malignant, and forty one with non malignant pleural effusion.
  • MEASUREMENTS AND RESULTS: Levels of CEA in pleural fluid was measured by IRMA CEA methods, INEP Belgrade.
  • Patients with lung cancer were found to have significantly higher CEA levels than patients with non malign pleural effusion.
  • CONCLUSION: CEA may represent a helpful adjunct to cytology in order to include malignancy as probable diagnosis, thus guiding the selection of patients for more invasive procedures.
  • [MeSH-major] Carcinoembryonic Antigen / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20088159.001).
  • [Journal-full-title] Medicinski arhiv
  • [ISO-abbreviation] Med Arh
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Bosnia and Herzegovina
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


22. Kanauchi N, Oizumi H, Honma T, Kato H, Endo M, Suzuki J, Fukaya K, Sadahiro M: Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer. Eur J Cardiothorac Surg; 2009 Apr;35(4):706-10; discussion 710-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of diffusion-weighted magnetic resonance imaging for predicting of tumor invasiveness for clinical stage IA non-small cell lung cancer.
  • Favorable results have been reported using this imaging system to differentiate between benign and malignant lesions in some organs, and to correlate with the degree of cell differentiation in lung cancer.
  • The purpose of this study was to assess the role of DWI for predicting tumor invasiveness of non-small cell lung cancers (NSCLC), especially for clinical stage IA patients.
  • Lung cancers that exhibited nodal, lymphovascular or pleural invasion were defined as invasive lung cancers.
  • We analyzed the associations between the pathological findings and the following preoperative clinical factors: age, gender, smoking history, preoperative CEA levels (<5.0 or >/=5.0ng/ml), preoperative tumor size, SUV max on PET/CT (<5.0 or >/=5.0) and DWI (positive or negative).
  • Multivariate analysis showed that DWI (p=0.005) was an independent predictive factor for tumor invasiveness.
  • CONCLUSION: Our results suggest that DWI might be a useful method for predicting tumor invasiveness for clinical stage IA NSCLC.
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Differentiation. Diffusion Magnetic Resonance Imaging. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests. Prognosis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19216085.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


23. Gardini A, Dubini A, Saragoni L, Padovani F, Garcea D: [Benign solitary fibrous tumor of the pancreas: a rare location of extra-pleural fibrous tumor. Single case report and review of the literature]. Pathologica; 2007 Feb;99(1):15-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Benign solitary fibrous tumor of the pancreas: a rare location of extra-pleural fibrous tumor. Single case report and review of the literature].
  • [Transliterated title] Tumore fibroso benigno solitario del pancreas: una rara localizzazione di tumore fibroso extrapleurico. Caso clinico e revisione della letteratura.
  • BACKGROUND/AIMS: Extra pleural solitary fibrous are very rare, but occasionally they appear in extraserosal soft tissues or parenchymatous organs, where their diagnosis is often a challenge.
  • In this report we describe the case of a patient with a single primary solitary fibrous tumor of the pancreatic head with a review of the literature.
  • The tumour showed immunoreactivity for CD34, CD99, bcl-2, vimentin and smooth muscle actin.
  • CONCLUSIONS: Extra pleural solitary fibrous tumor are often benign lesions.
  • The differential diagnosis is mainly based on immunohistochemistry.
  • The surgical approach is fundamental for the treatment of solitary fibrous tumour.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17566307.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 22
  •  go-up   go-down


24. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H: Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol; 2005 Mar;32(3):151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The morphological evaluation of cytological specimens from body cavity fluids presents difficulties in the differential diagnosis between benign reactive mesothelial (RM) cells and adenocarcinoma (AC) or malignant mesothelioma (MM).
  • The aim of our study was to investigate whether a panel of five different antibodies can offer reliable markers in the differential diagnosis of RM, AC, and MM in serous effusions.
  • [MeSH-major] Adenocarcinoma / diagnosis. Ascitic Fluid / pathology. Biomarkers, Tumor / metabolism. Mesothelioma / diagnosis. Pericardial Effusion / pathology. Pleural Effusion / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Epithelial Cells / metabolism. Epithelial Cells / pathology. Humans. Immunohistochemistry. Middle Aged

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690338.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


25. Rehnberg J, Zendehrokh N, Dejmek A: Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions. Anal Quant Cytol Histol; 2007 Aug;29(4):217-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lower proliferation rate in metastatic effusion mesothelial cells than in benign effusions.
  • OBJECTIVE: To determine the proliferation rates of mesothelial cells in metastatic and benign effusions.
  • STUDY DESIGN: Immunohistochemistry was performed on formalin-fixed pellets from 16 malignant and 9 benign clinical effusions.
  • Dual staining with antibodies against Ki-67 (MIB-1) and desmin was applied to all effusions to differentiate between benign mesothelial cells and malignant cells, and the proportions of desmin+/Ki-67+ and desmin+/Ki-67- cells were calculated.
  • RESULTS: In 7 malignant effusions no proliferating mesothelial cells were found, whereas some rate of proliferation could always be demonstrated in mesothelial cells in the benign effusions.
  • Further, the median proportions of proliferating cells, malignant 2% vs. benign 11%, differed significantly.
  • CONCLUSIONS: To our knowledge this finding has not been previously described, and it may have implications for both cytologic diagnosis and the understanding of tumor biology and the interaction between tumor cells and mesothelial cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879629.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Desmin; 0 / Ki-67 Antigen
  •  go-up   go-down


26. Watanabe T, Sato N, Miyamoto A, Kaimori M, Imai T: [Recurrence of thymoma as pleural dissemination 23-years after surgery]. Kyobu Geka; 2009 Jan;62(1):79-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recurrence of thymoma as pleural dissemination 23-years after surgery].
  • We thought that it was a benign chest wall tumor such as a neurogenic tumor by the findings of the chest computed tomography (CT).
  • Resection of the tumor was performed.
  • Neurogenic tumor was suspected by the frozen section.
  • Since she had undergone thymothymectomy 23-years ago, the tumor was considered to be a pleural recurrence of thymoma.
  • We thoroughly checked the chest CT again, and detected another tumor at the right of the thoracic vertebra.
  • Third surgery was performed and the tumor was resected.
  • We experienced recurrence of thymoma as pleural dissemination 23-years after surgery.
  • Thymomas are low-grade malignant tumor, but long-term clinical follow-up is necessary.
  • [MeSH-major] Pleural Neoplasms / secondary. Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasm Seeding

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19195191.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Daigeler A, Lehnhardt M, Langer S, Steinstraesser L, Steinau HU, Mentzel T, Kuhnen C: Clinicopathological findings in a case series of extrathoracic solitary fibrous tumors of soft tissues. BMC Surg; 2006;6:10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previously considered being of serosal origin and solely limited to the pleural cavity the tumor has been described in other locations, most particularly the head and neck.
  • Nine cases of this rare tumor entity are described in the course of this article with respect to clinicopathological data, follow-up and treatment results.
  • RESULTS: There were 6 females and 3 males, whose age at time of diagnosis ranged from 32 to 92 years (mean: 62.2 years).
  • CONCLUSION: ESFT usually behave as benign soft tissue tumors, although malignant variants with more aggressive local behaviour (local relapse) and metastasis may occur.
  • The risk of local recurrence and metastasis correlates to tumor size and histological status of surgical resection margins and may reach up to 10% even in so-called "benign" tumors.
  • Tumor specimens should be evaluated by experienced soft tissue pathologists.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1999 Nov;12(11):1034-42 [10574600.001]
  • [Cites] South Med J. 2004 Dec;97(12):1264-7 [15646769.001]
  • [Cites] APMIS. 2000 Sep;108(9):617-25 [11110050.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Langenbecks Arch Surg. 2000 Dec;385(8):521-5 [11201008.001]
  • [Cites] Am J Surg Pathol. 2001 Jul;25(7):900-10 [11420461.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1424-8 [11684960.001]
  • [Cites] J Am Acad Dermatol. 2002 Feb;46(2 Suppl Case Reports):S37-40 [11807468.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1241-5 [11846919.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1057-68 [11920476.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Arch Pathol Lab Med. 2003 Apr;127(4):432-9 [12683870.001]
  • [Cites] Ophthalmology. 2003 Jul;110(7):1442-8 [12867407.001]
  • [Cites] J Nucl Med. 2004 Jun;45(6):995-8 [15181135.001]
  • [Cites] Histopathology. 1991 Dec;19(6):515-22 [1786936.001]
  • [Cites] Am J Surg Pathol. 1994 Oct;18(10):992-8 [7522416.001]
  • [Cites] Am J Surg Pathol. 1995 Nov;19(11):1257-66 [7573687.001]
  • [Cites] Am J Clin Pathol. 1996 Sep;106(3):325-31 [8816589.001]
  • [Cites] Mod Pathol. 1997 May;10(5):443-50 [9160308.001]
  • [Cites] Virchows Arch. 1997 Jun;430(6):445-53 [9230909.001]
  • [Cites] Mod Pathol. 1997 Oct;10(10):1028-37 [9346183.001]
  • [Cites] Am J Surg Pathol. 1998 Dec;22(12):1501-11 [9850176.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):213-9 [10380040.001]
  • [Cites] J Hand Surg Br. 1999 Jun;24(3):370-2 [10433460.001]
  • [Cites] Hum Pathol. 2000 Jan;31(1):63-8 [10665915.001]
  • (PMID = 16824225.001).
  • [ISSN] 1471-2482
  • [Journal-full-title] BMC surgery
  • [ISO-abbreviation] BMC Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1523192
  •  go-up   go-down


28. Manosca F, Schinstine M, Fetsch PA, Sorbara L, Maria Wilder A, Brosky K, Erickson D, Raffeld M, Filie AC, Abati A: Diagnostic effects of prolonged storage on fresh effusion samples. Diagn Cytopathol; 2007 Jan;35(1):6-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specimens evaluated included four pleural (3 benign, 1 breast adenocarcinoma) and six peritoneal (2 ovarian adenocarcinomas, 1 malignant melanoma, 2 mesotheliomas, 1 atypical mesothelial) effusions.
  • [MeSH-major] Artifacts. Ascitic Fluid / pathology. Cytodiagnosis / methods. Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis. Specimen Handling / methods
  • [MeSH-minor] Adult. Biomarkers, Tumor. DNA, Neoplasm / analysis. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction. Time Factors

  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17173298.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


29. Miyamoto H, Montgomery EA, Epstein JI: Paratesticular fibrous pseudotumor: a morphologic and immunohistochemical study of 13 cases. Am J Surg Pathol; 2010 Apr;34(4):569-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) "plaque-like" consisting of dense fibrous tissue with clefts without significant inflammation identical to a pleural plaque (5 cases);.
  • Paratesticular fibrous pseudotumor looks histologically distinct from fibromatosis and inflammatory myofibroblastic tumor (IMT) seen in other organs, an assertion supported by negative stains for beta-catenin and ALK-1, respectively.
  • Although this lesion has different histologic patterns, presently it is not warranted to split it into 3 separate entities as all share the same clinical presentation, are biologically benign, and lack consistent immunohistochemical differences.

  • MedlinePlus Health Information. consumer health - Testicular Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20216379.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


30. Chua TC, Yan TD, Morris DL: Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management. Can J Surg; 2009 Feb;52(1):59-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mesothelioma is an asbestos-related tumour.
  • Mesothelioma in the thorax occurs on the pleura and is known as pleural mesothelioma.
  • Early diagnosis of peritoneal mesothelioma is often difficult because the early symptoms are often overlooked as being a benign ailment of the gastrointestinal tract.
  • Therefore, diagnosis often occurs at an advanced stage when disease is widespread throughout the peritoneal cavity.
  • [MeSH-major] Mesothelioma / diagnosis. Mesothelioma / therapy. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Asbestos / adverse effects. Biomarkers, Tumor. Chemotherapy, Cancer, Regional Perfusion. Diagnostic Imaging. Endoscopy, Gastrointestinal. Humans. Hyperthermia, Induced

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):515-25 [17031722.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):41-9 [17039392.001]
  • [Cites] Ann Surg Oncol. 2007 Mar;14(3):1105-13 [17206478.001]
  • [Cites] Ann Oncol. 2007 May;18(5):827-34 [17130182.001]
  • [Cites] Ann Surg Oncol. 2007 Jun;14(6):1807-17 [17342564.001]
  • [Cites] Ann Surg Oncol. 2007 Aug;14(8):2270-80 [17464543.001]
  • [Cites] Carcinogenesis. 2007 Sep;28(9):2047-52 [17434931.001]
  • [Cites] MedGenMed. 2007;9(2):32 [17955087.001]
  • [Cites] Br J Surg. 2007 Nov;94(11):1408-14 [17631678.001]
  • [Cites] Ann Surg Oncol. 2008 Jan;15(1):125-33 [18030535.001]
  • [Cites] Ann Oncol. 2008 Feb;19(2):370-3 [18156144.001]
  • [Cites] Nat Clin Pract Oncol. 2008 Mar;5(3):136-47 [18227828.001]
  • [Cites] CMAJ. 2008 Mar 11;178(6):677-8 [18332380.001]
  • [Cites] J Cell Biochem. 1999 Dec;76(2):181-8 [10618635.001]
  • [Cites] Br J Surg. 2000 Nov;87(11):1587-93 [11091251.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):247-50 [11500619.001]
  • [Cites] Am Surg. 2001 Oct;67(10):999-1003 [11603562.001]
  • [Cites] Semin Oncol. 2002 Feb;29(1):2-17 [11836664.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4169-75 [12154012.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2636-44 [12860938.001]
  • [Cites] Tumori. 2003 May-Jun;89(3):269-73 [12908781.001]
  • [Cites] Clin Lung Cancer. 2003 Nov;5(3):177-81 [14667274.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4560-7 [14673042.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 1:S21-3 [15261428.001]
  • [Cites] Ann Intern Med. 1982 Jun;96(6 Pt 1):746-55 [7091938.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Lancet. 1985 Nov 2;2(8462):977-81 [2414612.001]
  • [Cites] Acta Cytol. 1987 May-Jun;31(3):369-73 [3035848.001]
  • [Cites] Environ Res. 1987 Oct;44(1):103-16 [3115771.001]
  • [Cites] Am J Pathol. 1987 Dec;129(3):448-62 [2827488.001]
  • [Cites] Exp Pathol. 1987;32(3):129-52 [3436395.001]
  • [Cites] J Cancer Res Clin Oncol. 1992;118(7):547-50 [1624547.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] Cancer Res. 1995 Feb 15;55(4):792-8 [7850791.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):124-32 [7857141.001]
  • [Cites] Am J Physiol. 1995 Mar;268(3 Pt 1):L471-80 [7900829.001]
  • [Cites] Environ Health Perspect. 1994 Dec;102 Suppl 10:131-6 [7705288.001]
  • [Cites] Cancer Treat Res. 1996;82:359-74 [8849962.001]
  • [Cites] Cancer Res. 1996 Dec 1;56(23):5334-8 [8968079.001]
  • [Cites] Histopathology. 1997 May;30(5):403-18 [9181361.001]
  • [Cites] Eur J Surg Oncol. 2005 Feb;31(1):53-8 [15642426.001]
  • [Cites] Tumori. 2005 Jan-Feb;91(1):1-5 [15849996.001]
  • [Cites] Lung Cancer. 2005 Jul;49 Suppl 1:S3-8 [15950797.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Int J Occup Environ Health. 2005 Jul-Sep;11(3):254-8 [16130966.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1564-73 [16221779.001]
  • [Cites] N Engl J Med. 2005 Oct 13;353(15):1591-603 [16221782.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):447-53 [16428485.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):405-12 [16485159.001]
  • [Cites] J Exp Clin Cancer Res. 2003 Dec;22(4 Suppl):41-5 [16767905.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jul 5;103(27):10397-402 [16798876.001]
  • [Cites] Ann Oncol. 2006 Nov;17(11):1615-9 [16600983.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1076:871-81 [17119263.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):500-8 [17151789.001]
  • (PMID = 19234654.001).
  • [ISSN] 1488-2310
  • [Journal-full-title] Canadian journal of surgery. Journal canadien de chirurgie
  • [ISO-abbreviation] Can J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 1332-21-4 / Asbestos
  • [Number-of-references] 54
  • [Other-IDs] NLM/ PMC2637623
  •  go-up   go-down


31. Lu C, Ji Y, Shan F, Guo W, Ding J, Ge D: Solitary fibrous tumor of the pleura: an analysis of 13 cases. World J Surg; 2008 Aug;32(8):1663-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura: an analysis of 13 cases.
  • BACKGROUND: Solitary fibrous tumor of the pleura is a rare soft-tissue tumor.
  • In search of appropriate diagnosis and treatment methods, we present our experience with 13 patients.
  • Seven tumors were malignant and the other six were benign.
  • Immunohistochemical staining showed nestin was positive in three malignant solitary fibrous tumors of pleura (3/7), which were negative for CD34.
  • CONCLUSION: Ultrasonography-guided core needle biopsy combined with immunohistochemical analysis might be a safe and rapid method to provide a confirmatory diagnosis before resection.
  • We speculate that CD34-negative and nestin-positive might be a malignant marker for solitary fibrous tumor of pleura.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / diagnosis. Pleural Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / methods. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Radiography, Thoracic. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1998 May;32(5):423-32 [9639117.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):305-9 [12973709.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Eur J Cardiothorac Surg. 1998 Nov;14(5):453-9 [9860200.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):814-20 [7518652.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):489-92 [1755106.001]
  • [Cites] J Comput Assist Tomogr. 2002 Mar-Apr;26(2):174-9 [11884769.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • [Cites] Jpn J Clin Oncol. 1998 Feb;28(2):86-91 [9544821.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):264-9 [17075563.001]
  • [Cites] Differentiation. 1997 Feb;61(3):151-9 [9084133.001]
  • [Cites] Chest. 2000 Mar;117(3):897-900 [10713024.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):428-31 [7535740.001]
  • [Cites] Acta Neuropathol. 2001 Oct;102(4):349-54 [11603810.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Chest. 1997 Nov 5;112(5):1424-8 [9367487.001]
  • [Cites] Chest. 2004 Mar;125(3):1144-7 [15006980.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Dec;12 (6):928-30 [9489884.001]
  • (PMID = 18427887.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


32. Hollevoet K, Nackaerts K, Thimpont J, Germonpré P, Bosquée L, De Vuyst P, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP: Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med; 2010 Mar 15;181(6):620-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RATIONALE: Soluble mesothelin (SM) is currently the reference serum biomarker of malignant pleural mesothelioma (MPM).
  • METHODS: A total of 507 participants were enrolled in six cohorts: healthy control subjects (n = 101), healthy asbestos-exposed individuals (n = 89), and patients with benign asbestos-related disease (n = 123), benign respiratory disease (n = 46), lung cancer (n = 63), and MPM (n = 85).
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Mesothelioma / diagnosis. Pleural Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20075387.001).
  • [ISSN] 1535-4970
  • [Journal-full-title] American journal of respiratory and critical care medicine
  • [ISO-abbreviation] Am. J. Respir. Crit. Care Med.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


33. Mohamed F, Vincent N, Cottier M, Peoc'h M, Merrouche Y, Patouillard B, Paul S, Genin C: Improvement of malignant serous effusions diagnosis by quantitative analysis of molecular claudin 4 expression. Biomarkers; 2010 Jun;15(4):315-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improvement of malignant serous effusions diagnosis by quantitative analysis of molecular claudin 4 expression.
  • Our aim was to improve the cytology diagnosis of malignancy in serous fluids with the quantification of claudins compared with various classic molecular markers using real-time reverse transcriptase-polymerase chain reaction (RT-PCR) method.
  • Peritoneal or pleural effusions of 56 patients were assessed as malignant from histological analysis and 19 as benign.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Membrane Proteins / metabolism. Neoplasms / diagnosis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / genetics. Antigens, Neoplasm / metabolism. Ascitic Fluid / metabolism. Cell Adhesion Molecules / genetics. Cell Adhesion Molecules / metabolism. Claudin-1. Claudin-4. Claudins. Female. Humans. Keratin-19 / genetics. Keratin-19 / metabolism. Keratin-20 / genetics. Keratin-20 / metabolism. Male. Middle Aged. Mucin-1 / genetics. Mucin-1 / metabolism. Mucins / genetics. Mucins / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20175704.001).
  • [ISSN] 1366-5804
  • [Journal-full-title] Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals
  • [ISO-abbreviation] Biomarkers
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CLDN1 protein, human; 0 / CLDN18 protein, human; 0 / CLDN4 protein, human; 0 / Cell Adhesion Molecules; 0 / Claudin-1; 0 / Claudin-4; 0 / Claudins; 0 / EPCAM protein, human; 0 / Keratin-19; 0 / Keratin-20; 0 / MUC19 protein, human; 0 / Membrane Proteins; 0 / Mucin-1; 0 / Mucins; 0 / Receptors, Cell Surface; 0 / carcinoembryonic antigen binding protein, human
  •  go-up   go-down


34. Zeren EH, Demirag F: Benign and Malignant Mesothelial Proliferation. Surg Pathol Clin; 2010 Mar;3(1):83-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and Malignant Mesothelial Proliferation.
  • Malignant mesothelioma (MM) is a rare primary malignant tumor of the surface serosal cells.
  • The diagnosis of MM is challenging with a broad differential diagnosis.
  • For many decades, studies have focused on distinguishing MM from other types of cancer; however, benign mesothelial cell hyperplasia, especially in small biopsies, has emerged as a major problem.
  • The features of pleural lesions are somewhat different from peritoneal diseases, and this article primarily focuses on pleural diseases.
  • Thorough interpretation and correlation of clinical, radiologic, and pathologic findings are essential for a correct diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 26839028.001).
  • [ISSN] 1875-9181
  • [Journal-full-title] Surgical pathology clinics
  • [ISO-abbreviation] Surg Pathol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Malignant mesothelioma / Mesothelial proliferations / Metastatic carcinoma / Pleural effusion
  •  go-up   go-down


35. Radak V, Radovanović D, Grubor N, Micev M, Colović R: [Solitary fibrous tumor of the visceral pleura of the right lung base]. Srp Arh Celok Lek; 2006 Sep-Oct;134(9-10):441-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary fibrous tumor of the visceral pleura of the right lung base].
  • Within thorax, they usually originate from pleura, most frequently the visceral one.
  • Authors present a 67- year old male in whom the tumor was diagnosed during the investigation for dyspnea.
  • During operation, solitary, well circumscribed, firm, ruber-like tumour, 11 x 10 x 9 cm in diameter, covered with serosa, arising from the visceral pleura of the base of the right lung was easily excised.
  • The classical histological and immunohistochemical examinations confirmed the diagnosis of benign fibrous tumor.
  • [MeSH-major] Fibroma / pathology. Pleural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17252914.001).
  • [ISSN] 0370-8179
  • [Journal-full-title] Srpski arhiv za celokupno lekarstvo
  • [ISO-abbreviation] Srp Arh Celok Lek
  • [Language] srp
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Serbia and Montenegro
  •  go-up   go-down


36. Jiang B, Wu GP, Zhao YJ, Wang SC: Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer. Diagn Cytopathol; 2008 Dec;36(12):849-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription expression and clinical significance of TTF-1 mRNA in pleural effusion of patients with lung cancer.
  • The aim of this study was to evaluate diagnostic utility of thyroid transcription factor 1 (TTF-1) mRNA in pleural effusions (PEs) of patients with lung cancer, especially primary pulmonary adenocarcinoma (PPA).
  • Transcription levels of TTF-1 were detected by reverse transcription polymerase chain reaction (RT-PCR) in PEs of patients with lung cancer (56 cases) and with lung benign diseases (44 cases).
  • The expression rate of TTF-1 mRNA was significantly higher in PEs of patients with lung cancer (73.2%) than with benign lung diseases (0%).
  • As a molecular marker of detecting pleural micrometastasis, TTF-1 mRNA may be helpful to diagnose the cancer cells in PEs of patients with lung cancer, especially with PPA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / genetics. Lung Neoplasms / diagnosis. Nuclear Proteins / genetics. Pleural Effusion, Malignant / diagnosis. RNA, Messenger / genetics. Transcription Factors / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18855882.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


37. Rodríguez Portal JA, Rodríguez Becerra E, Rodríguez Rodríguez D, Alfageme Michavila I, Quero Martínez A, Diego Roza C, León Jiménez A, Isidro Montes I, Cebollero Rivas P: Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. Cancer Epidemiol Biomarkers Prev; 2009 Feb;18(2):646-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
  • BACKGROUND: Malignant pleural mesothelioma (MPM) results from malignant transformation of mesothelial cells.
  • Past asbestos exposure represents a major risk factor for MPM and other benign pleural disease.
  • The aim of this study was to investigate serum levels of SMRP in malignant and nonmalignant asbestos-related pleural disease.
  • PATIENTS: Four groups of patients were investigated: group 1 composed of 48 healthy subjects, group 2 composed of 177 patients with previous asbestos exposure and no pleural disease, group 3 composed of 36 patients with MPM, and group 4 composed of 101 patients with previous asbestos exposure and benign pleural disease.
  • Subjects exposed to asbestos had higher SMRP concentrations than normal control subjects regardless of the presence of pleural disease.
  • The SMRP level at 0.55 nmol/L/L was determined as the most optimal cutoff value with resulting sensitivity and specificity of 72% and 72% for the diagnosis of MPM.
  • CONCLUSIONS: These data attest to good diagnostic sensitivity and specificity of SMRP for the diagnosis of malignant mesothelioma.
  • [MeSH-major] Asbestosis / blood. Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Pleural Neoplasms / blood

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19190155.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin
  •  go-up   go-down


38. Chamadol N, Laopaiboon V, Promsorn J, Bhudhisawasd V, Pagkhem A, Pairojkul C: Gastrointestinal stromal tumor: computed tomographic features. J Med Assoc Thai; 2009 Sep;92(9):1213-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal stromal tumor: computed tomographic features.
  • The tumor sites, sizes, borders, growth patterns, patterns of enhancement, and sign of malignancy were evaluated.
  • The findings of benign and malignant GISTs were compared.
  • The others were small bowel (43.75%), and tumor size larger than 5 cm.
  • The CT signs of malignancy found were invasion of the adjacent organ(s) (62.5%), lymphadenopathy (25%), liver metastasis/nodule (18.75%), ascites (6.25%), perilesional fat plane stranding (93.75%), and pleural effusion (6.25%).
  • The CT findings cannot be used as a single tool for differentiating the benign from malignant GISTs.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19772182.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


39. Fibla JJ, Gómez G, Salord N, Penagos JC, Estrada G, León C: [Giant solitary fibrous tumor of the pleura]. Cir Esp; 2005 May;77(5):290-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Giant solitary fibrous tumor of the pleura].
  • [Transliterated title] Tumor fibroso solitario pleural gigante.
  • Primitive neoplasms of the pleura are uncommon.
  • Solitary fibrous tumor of the pleura (SFTP) is a benign variety of primitive pleural tumor, which is usually asymptomatic and discovered as an incidental finding.
  • [MeSH-major] Pleural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16420936.001).
  • [ISSN] 0009-739X
  • [Journal-full-title] Cirugía española
  • [ISO-abbreviation] Cir Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


40. Shu J, Sun G, Liu H, Liu J: Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions. Acta Oncol; 2007;46(7):1004-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical utility of vascular endothelial growth factor in diagnosing malignant pleural effusions.
  • While the early diagnosis of cancer has been fully respected, it is still however often difficult for clinicians to confirm malignant pleural effusions (PE), which essentially indicate the end-stage cancer.
  • It has now been demonstrated that vascular endothelial growth factor (VEGF) is a pivotal angiogenesis factor and associated with tumor growth and metastasis.
  • For each eligible case, the VEGF levels of pleural fluid (PF) and serum were examined simultaneously using enzyme immunoassay.
  • The reference standard for malignant PE was clinical evaluation and PF cytology with pleural biopsy, other examination and follow-up added as needed.
  • According to the final diagnoses, 81 qualified cases were grouped as malignant (n=32) and benign (n=49) PE.
  • For PF VEGF level, the mean in malignant group was higher than that in benign group (1358+/-1493 pg/mL vs. 422+/-317 pg/mL, p=0.001).
  • [MeSH-major] Biomarkers, Tumor / analysis. Pleural Effusion, Malignant / diagnosis. Vascular Endothelial Growth Factor A / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17917830.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


41. Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Kadota E, Nonomura A: 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis. Pathol Int; 2010 May;60(5):395-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 9p21 deletion in the diagnosis of malignant mesothelioma, using fluorescence in situ hybridization analysis.
  • Previous studies showed that this alteration might be useful for differentiating benign from malignant mesothelial tumors in cytology and surgical specimens.
  • The purpose of this study is to evaluate the diagnostic utility of 9p21 homozygous deletion assessed by FISH in mesothelial neoplasm and hyperplasia of Japanese patients using paraffin-embedded tissue.
  • In contrast, no cases of adenomatoid tumor, benign mesothelial multicystic tumor, reactive mesothelial hyperplasia or pleuritis showed 9p21 deletion (P < 0.005).
  • 9p21 homozygous deletion correlated well with p16 protein expression in the tumor cells.
  • [MeSH-major] Chromosomes, Human, Pair 9. Genes, p16. Heart Neoplasms / diagnosis. In Situ Hybridization, Fluorescence / methods. Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. DNA, Neoplasm / analysis. Epithelium / pathology. Female. Gene Deletion. Gene Dosage. Humans. Pericardium / metabolism. Pericardium / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518890.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


42. Afify A, Lynne LC, Howell L: Correlation of cytologic examination with ELISA assays for hyaluronan and soluble CD44v6 levels in evaluation of effusions. Diagn Cytopathol; 2007 Feb;35(2):105-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hyaluronan (HA) and its major cell surface receptor, CD44, play an important role in tumor growth, proliferation, neovascularization, and invasion.
  • Although studies have proposed the use of serum HA and soluble CD44, specifically soluble CD44v6 (sCD44v6) levels, as a tumor markers, its diagnostic utility in body fluid samples has not been clearly established.
  • The purpose of this study was to correlate HA and sCD44v6 levels in effusions with the cytology diagnosis and to assess their usefulness in differentiating between malignant and nonmalignant effusions.
  • Using benign effusions as control and the upper limits of its mean levels for HA (10.5 microg/mL) as the positive boundary value, HA levels exceeded the boundary line in 17 out of 20 malignant effusions and 2 out of 10 benign effusions.
  • Meanwhile, sCD44v6 exceeded the boundary line (27 ng/mL) in 18 out of 20 malignant effusions and 3 out of 10 benign effusions.
  • The calculated sensitivity and specificity of this assay to the diagnosis of malignant effusions were 85 and 80% for HA and 90 and 70% for CD44v6, respectively.
  • We conclude that the HA and sCD44v6 levels in body fluids correlate with the cytology diagnosis and could be used as an ancillary study in cytology to differentiate nonmalignant from malignant effusions.
  • [MeSH-major] Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Ascitic Fluid / pathology. Biomarkers, Tumor / metabolism. Glycoproteins / metabolism. Hyaluronic Acid / metabolism. Pleural Effusion / metabolism. Pleural Effusion / pathology
  • [MeSH-minor] Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Humans. Pleural Effusion, Malignant / diagnosis. Pleural Effusion, Malignant / metabolism. Pleural Effusion, Malignant / pathology. Retrospective Studies. Sensitivity and Specificity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17230576.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44v6 antigen; 0 / Glycoproteins; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


43. Ohar JA, Ampleford EJ, Howard SE, Sterling DA: Identification of a mesothelioma phenotype. Respir Med; 2007 Mar;101(3):503-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite the strong association of asbestos exposure to mesothelioma, only a fraction of persons exposed develop this neoplasm which is characterized by long latency and shortened survival.
  • To identify a more extensive set of traits that would define a mesothelioma phenotype for the purpose of genetic analysis, we set to determine characteristics that distinguish mesothelioma patients from others exposed to asbestos and to identify factors that predict the presence of mesothelioma over other mesenchymal tumors of the peritoneum and carcinoma metastatic to the pleura.
  • We compared demographics in four asbestos-exposed groups (controls n=347, bronchogenic cancer n=67, mesothelioma n=179 and benign asbestos-induced lung disease (BALD) n=3757).
  • We found that compared to other asbestos-exposed groups, subjects with mesothelioma were younger at first asbestos exposure, had a greater risk of a second cancer diagnosis (odds ratio=3.29), had a longer disease latency, and had a greater risk of cancer among first-degree relatives (point estimate for risk 2.93; 95% CI 2.5-3.5).
  • Thoracic tumor location, work exposure and male gender were consistently associated with shortened survival (1.9+/-1.3 years).
  • We conclude that thoracic tumor location, work exposure, male gender, long latency, early age at first exposure, presence of a second cancer, and first-degree relative with cancer define a phenotype that sets mesothelioma patients with a short survival apart from other asbestos-exposed individuals.
  • [MeSH-minor] Age Factors. Aged. Educational Status. Family Health. Female. Humans. Male. Middle Aged. Neoplasms, Multiple Primary. Occupational Exposure / adverse effects. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / mortality. Phenotype. Pleural Neoplasms / genetics. Pleural Neoplasms / mortality. Risk Factors. Sex Factors. Smoking / adverse effects


44. Painter JN, Tapanainen H, Somer M, Tukiainen P, Aittomäki K: A 4-bp deletion in the Birt-Hogg-Dubé gene (FLCN) causes dominantly inherited spontaneous pneumothorax. Am J Hum Genet; 2005 Mar;76(3):522-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary spontaneous pneumothorax (PSP), a condition in which air enters the pleural space and causes secondary lung collapse, is mostly sporadic but also occurs in families.
  • Mutations in FLCN are also responsible for Birt-Hogg-Dubé (BHD) syndrome (a dominantly inherited disease characterized by benign skin tumors, PSP, and diverse types of renal cancer) and, rarely, are detected in sporadic renal and colorectal tumors.
  • [MeSH-minor] Base Sequence. DNA / genetics. Exons. Female. Finland. Genes, Dominant. Humans. Male. Molecular Sequence Data. Pedigree. Phenotype. Proto-Oncogene Proteins. Tumor Suppressor Proteins


45. Baas P, Triesscheijn M, Burgers S, van Pel R, Stewart F, Aalders M: Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid. Chest; 2006 Mar;129(3):718-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence detection of pleural malignancies using 5-aminolaevulinic acid.
  • STUDY OBJECTIVE: Although the use of video-assisted thoracoscopy has improved the diagnostic accuracy in patients presenting with pleural diseases, not all biopsies performed are conclusive and staging of the disease is not always optimal.
  • Fluorescence diagnosis (FD) with 5-aminolaevulinic acid (5-ALA) has been used in the diagnostic workup for various malignancies.
  • The impact of 5-ALA-mediated FD on diagnosis and staging during video-assisted thoracoscopy was examined.
  • PATIENTS: Twenty-six patients with nonconclusive pleural effusions who were scheduled for video-assisted thoracoscopy.
  • After conventional inspection with white light, fluorescence inspection of the pleural cavity was performed (D-LIGHT Auto Fluorescent System; Karl Storz; Tuttlingen, Germany).
  • A definitive diagnosis was obtained in 24 of 25 cases, with malignant mesothelioma in 15 cases, other malignancies in 5 cases, one infection, and three benign diseases.
  • Upstaging occurred in four patients (unsuspected tumor deposits) due to FD examination.
  • CONCLUSIONS: FD using 5-ALA in the pleural cavity is feasible with limited side effects when used in addition to white light inspection.
  • [MeSH-major] Aminolevulinic Acid. Photosensitizing Agents. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Feasibility Studies. Female. Humans. Male. Mesothelioma / diagnosis. Middle Aged. Prospective Studies. Thoracic Surgery, Video-Assisted. Thoracoscopy

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16537873.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


46. Imai T, Suga M, Kaimori M, Hiyama M, Yokoyama K, Kurotaki H: Peripheral pulmonary papillary adenocarcinoma with prominent cilia: report of a rare case that was difficult to diagnose preoperatively. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):949-57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In pulmonary cytology, the existence of cilia is considered cytologic evidence of benign cells because it is generally considered that cilia could not be identified by light microscopic observation of pulmonary adenocarcinoma.
  • Computed tomography revealed a lung tumor.
  • After antibiotic therapy, the tumor was surgically excised.
  • Histologically, the tumor was diagnosed as papillary adenocarcinoma with cilia and diffuse pleural dissemination was observed.
  • Pulmonary papillary adenocarcinoma with cilia should be considered in the differential diagnosis of atypical cells in pulmonary cytology.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / pathology. Cilia / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Preoperative Care
  • [MeSH-minor] Diagnosis, Differential. Fatal Outcome. Female. Humans. Immunohistochemistry. Intraoperative Care. Lung / pathology. Middle Aged. Radiography, Thoracic

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053576.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Moschos C, Porfiridis I, Psallidas I, Kollintza A, Stathopoulos GT, Papiris SA, Roussos C, Kalomenidis I: Osteopontin is upregulated in malignant and inflammatory pleural effusions. Respirology; 2009 Jul;14(5):716-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteopontin is upregulated in malignant and inflammatory pleural effusions.
  • In the present study, we asked whether pleural fluid (PF) and serum OPN concentrations differed between patients with pleural effusions of different aetiologies, and whether assessment of OPN levels was useful for diagnostic purposes.
  • METHODS: One hundred and nine consecutive patients with pleural effusions of different aetiologies were recruited prospectively during daily clinics.
  • RESULTS: PF OPN levels were 10-fold higher in exudates than in transudates and were significantly correlated with markers of pleural inflammation and vascular hyper-permeability, such as PF/serum LDH or protein ratios, PF protein and PF vascular endothelial growth factor levels.
  • Patients with malignant pleural effusions had higher PF and lower serum OPN concentrations than those with benign disease.
  • CONCLUSIONS: OPN levels were elevated in exudative pleural effusions, as compared with the levels in blood or transudative pleural effusions.
  • [MeSH-major] Lung Diseases / metabolism. Lung Neoplasms / metabolism. Osteopontin / metabolism. Pleural Effusion / metabolism. Pleural Effusion, Malignant / metabolism. Pleural Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Pneumonia / complications. Pneumonia / diagnosis. Pneumonia / metabolism. Prospective Studies. Tuberculosis / complications. Tuberculosis / diagnosis. Tuberculosis / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19476604.001).
  • [ISSN] 1440-1843
  • [Journal-full-title] Respirology (Carlton, Vic.)
  • [ISO-abbreviation] Respirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin
  •  go-up   go-down


48. Chaib E, Gama-Rodrigues J, Ribeiro MA Jr, Herman P, Saad WA: Hepatic adenoma. Timing for surgery. Hepatogastroenterology; 2007 Jul-Aug;54(77):1382-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Hepatic adenoma (HA) is a rare benign tumor of the liver.
  • Tumor resection has been recommended for symptomatic or enlarging HA because of the risk of intraperitoneal, intrahepatic hemorrhage or even the development of hepatocellular carcinoma.
  • From 1989 to 2003 we reviewed the medical records and radiology files of 28 patients with a proved diagnosis of hepatic adenoma.
  • There was no postoperative death and the complications were: bile leakage (re-operation) one patient, intraperitoneal abscess (re-operation) one patient, pleural effusion two patients, venous thrombosis one patient and wound infection one patient.
  • CONCLUSIONS: We recommend that since the diagnosis has been well-established both enucleation or anatomically based resections of hepatic adenoma should be performed in all cases mainly in female patients taking oral contraceptives with tumors greater than 3cm for the risk of hepatic hemorrhage or even when malignancy cannot be excluded.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17708259.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


49. Kyle CC, Wingo MS, Carey RI, Leveillee RJ, Bird VG: Diagnostic yield of renal biopsy immediately prior to laparoscopic radiofrequency ablation: a multicenter study. J Endourol; 2008 Oct;22(10):2291-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mean tumor size was 3.0 cm (range 1.0-6.9).
  • Final pathology revealed renal cell carcinoma in 95, oncocytic neoplasm in 26, and angiomyolipoma in 9.8 patients were considered to have nondiagnostic biopsies.
  • In this group, final pathology revealed benign cysts in 3, inconclusive specimens in 3, fibrosis in 1, and normal tissue in 1.
  • Hence, a clear diagnosis was possible in 130 of 138 patients, which is 94.2%.
  • Eight patients had perioperative complications, including low-grade fevers (2) perirenal/retroperitonal hematoma (2), pleural tear/pneumothorax (2), CHF exacerbation, and wound infection.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18937593.001).
  • [ISSN] 1557-900X
  • [Journal-full-title] Journal of endourology
  • [ISO-abbreviation] J. Endourol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


50. Kayser K, Hoshang SA, Metze K, Goldmann T, Vollmer E, Radziszowski D, Kosjerina Z, Mireskandari M, Kayser G: Texture- and object-related automated information analysis in histological still images of various organs. Anal Quant Cytol Histol; 2008 Dec;30(6):323-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS: A generalized algorithm was developed that permits the evaluation of diagnosis-associated image features obtained from hematoxylin-eosin-stained histopathologic slides.
  • The procedure was tested for screening of tumor tissue vs. tumor-free tissue in 1,442 cases of various organs.
  • Tissue samples studied include colon, lung, breast, pleura, stomach and thyroid.
  • RESULTS: The accuracy of automated crude classification was between 95% and 100% based upon a learning set of 10 cases per diagnosis class.
  • The algorithm can also distinguish between benign and malignant tumors of colon, between epithelial mesothelioma and pleural carcinomatosis or between different common pulmonary carcinomas.
  • It is a promising technique that can assist tissue-based diagnosis and be expanded to virtual slide evaluation.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160697.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


51. Huang WW, Tsao SM, Lai CL, Su CC, Tseng CE: Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. Pathology; 2010 Apr;42(3):224-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma.
  • AIMS: Cytology fails to detect neoplastic cells in 40-50% of cases of malignant pleural effusion, a condition that frequently accompanies lung adenocarcinoma.
  • Published reports of diagnostic sensitivity of various tumour markers are inconsistent, and optimal cut-off points have not been determined.
  • This study aimed to evaluate the ability of three markers to discriminate lung adenocarcinoma-associated malignant pleural effusion (LAC-MPE) from benign effusion.
  • METHODS: Pleural effusion samples were collected from 41 patients with LAC-MPE, and from 93 with various benign conditions.
  • RESULTS: Her-2/neu, Cyfra 21-1, and CEA vary in their diagnostic accuracy to differentiate LAC-MPE from benign pleural effusion: 79.85%, 88.81%, and 94.03%, respectively.
  • The results of the present study may help clinicians decide whether to obtain a cytological/histological specimen by invasive means to investigate a possible diagnosis of malignancy.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, Neoplasm / analysis. Carcinoembryonic Antigen / analysis. Keratin-19 / analysis. Lung Neoplasms / diagnosis. Pleural Effusion / metabolism. Receptor, ErbB-2 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20350214.001).
  • [ISSN] 1465-3931
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / antigen CYFRA21.1; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


52. Vodicka J, Spidlen V, Klecka J, Simánek V, Safránek J: [Use of the KLS Martin Nd:YAG laser MY 40 13 in lung parenchyma surgery]. Rozhl Chir; 2009 May;88(5):248-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Nd:YAG laser MY 40 1.3 has been developed to be employed in lung tumor resections.
  • In 12 subjects, lung metastases of malignant tumors were detected, 3 subjects suffered from primary lung carcinoma and two from benign lung lesions.
  • The two benign lesions were managed in a similar way.
  • Furthermore, it can be successfully used in a numer of other surgical procedures, such as management of pleural adhesions, lung biopsies, resections of emphysematous bullae, resections of benign lung tumors, dissections of inerlobal fissures, etc., where the method can fully replace staplers.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642342.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


53. Kato Y, Tsuta K, Seki K, Maeshima AM, Watanabe S, Suzuki K, Asamura H, Tsuchiya R, Matsuno Y: Immunohistochemical detection of GLUT-1 can discriminate between reactive mesothelium and malignant mesothelioma. Mod Pathol; 2007 Feb;20(2):215-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The separation of benign reactive mesothelium (RM) from malignant mesothelial proliferation can be a major challenge.
  • To date, however, no immunohistochemical marker that allows unequivocal discrimination of RM from malignant pleural mesothelioma (MPM) has been available.
  • GLUT-1 is largely undetectable by immunohistochemistry in normal epithelial tissues and benign tumors, but is expressed in a variety of malignancies.
  • Recently, in fact, some studies have shown that GLUT-1 expression is useful for distinguishing benign from malignant lesions.
  • GLUT-1 is a sensitive and specific immunohistochemical marker enabling differential diagnosis of RM from MPM, whereas it cannot discriminate MPM from lung carcinoma.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Glucose Transporter Type 1 / metabolism. Immunoenzyme Techniques. Mesothelioma / metabolism. Pleural Neoplasms / metabolism. Pleurisy / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Membrane / metabolism. Cell Membrane / pathology. Diagnosis, Differential. Humans. Lung Neoplasms / metabolism. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192790.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1
  •  go-up   go-down


54. Savic S, Franco N, Grilli B, Barascud Ade V, Herzog M, Bode B, Loosli H, Spieler P, Schönegg R, Zlobec I, Clark DP, Herman JG, Bubendorf L: Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology. Chest; 2010 Jul;138(1):137-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology.
  • The aim of our study was to test chromosomal aberrations detected by fluorescence in situ hybridization (FISH) in the diagnosis of MM in effusion cytology and to explore the potential role of p16, p14, and p15 gene methylation as an alternative mechanism of tumor suppressor gene inactivation.
  • METHODS: Fifty-two effusions of biopsy-proven MM and 28 benign effusions were retrospectively analyzed by multitarget FISH assay for aberrations of chromosomes 3, 7, 17, and 9p21.
  • All benign effusions were FISH negative.
  • Four of five FISH-negative biopsy specimens showed promoter methylation in p16 and p14 as compared with one of 12 benign controls.
  • CONCLUSIONS: FISH is a sensitive and highly specific method for the definitive diagnosis of MM in effusion cytology.
  • In the subset of FISH-negative MM, tumor suppressor genes on the chromosomal region 9p21 are often inactivated by promoter methylation.
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Mesothelioma / pathology. Pleural Effusion, Malignant / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Genes, p16. Humans. Male. Middle Aged. Pleural Effusion / diagnosis. Polymerase Chain Reaction. Retrospective Studies

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139227.001).
  • [ISSN] 1931-3543
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


55. Wang HY, Fan QH, Gong QX, Wang Z: [Clinicopathologic characteristics of hemangiopericytoma/solitary fibrous tumor with giant cells]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):169-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic characteristics of hemangiopericytoma/solitary fibrous tumor with giant cells].
  • OBJECTIVE: To study the pathological characteristics, diagnosis and differential diagnoses of hemangiopericytoma-solitary fibrous tumor with giant cells.
  • Seven patients underwent tumor excision and were well and without tumor recurrence upon the clinical follow-up.
  • CONCLUSIONS: Hemangiopericytoma-solitary fibrous tumor with giant cells is an intermediate soft tissue tumor.
  • Histologically, the tumor should be distinguished from giant cell fibroblastoma, pleomorphic hyalinzing angiectatic tumor of soft part and angiomatoid fibrous histiocytoma.
  • [MeSH-minor] Adult. Antigens, CD / metabolism. Antigens, CD34 / metabolism. Cell Adhesion Molecules / metabolism. Dermatofibrosarcoma / pathology. Diagnosis, Differential. Female. Follow-Up Studies. Histiocytoma, Benign Fibrous / pathology. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Recurrence, Local. Proto-Oncogene Proteins c-bcl-2 / metabolism. Soft Tissue Neoplasms / pathology. Solitary Fibrous Tumor, Pleural / metabolism. Solitary Fibrous Tumor, Pleural / pathology. Solitary Fibrous Tumor, Pleural / surgery. Young Adult

  • Genetic Alliance. consumer health - Hemangiopericytoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575851.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


56. Giesel FL, Bischoff H, von Tengg-Kobligk H, Weber MA, Zechmann CM, Kauczor HU, Knopp MV: Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome. Chest; 2006 Jun;129(6):1570-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dynamic contrast-enhanced MRI of malignant pleural mesothelioma: a feasibility study of noninvasive assessment, therapeutic follow-up, and possible predictor of improved outcome.
  • The aims of this study were to evaluate the feasibility of DCE-MRI in malignant pleural mesothelioma (MPM), to differentiate benign from pathologic tissue and compare pharmacokinetic with clinical parameters and survival in order to map out its microcirculation; and to compare pharmacokinetic with clinical parameter and survival in order to improve our understanding of the in vivo biology of this malignancy.
  • METHODS: Nineteen patients with a diagnosis of MPM who were scheduled to receive chemotherapy with gemcitabine were enrolled in the study.
  • Tumor regions were characterized by the pharmacokinetic parameters amplitude (Amp), redistribution rate constant (kep), and elimination rate constant (kel).
  • Kinetic parameters of tumor tissue and normal tissue were compared using the Student t test.
  • RESULTS: Normal and tumor tissue could be distinguished by the pharmacokinetic parameters Amp and kel (p </= 0.001).
  • Clinical responders had a median kep value within the tumor of 2.6 min, while nonresponders showed a higher value (3.6 min), which coincided with longer survival (780 days vs 460 days).
  • CONCLUSIONS: DCE-MRI can be used in patients with MPM to assess tumor microvascular properties and to demonstrate tumor heterogeneity for therapy monitoring.
  • High pretherapeutic values of kep within the tumor correlated with a poor overall response to therapy.
  • [MeSH-major] Contrast Media / pharmacokinetics. Gadolinium DTPA / pharmacokinetics. Magnetic Resonance Imaging. Mesothelioma / metabolism. Mesothelioma / pathology. Pleural Neoplasms / metabolism. Pleural Neoplasms / pathology

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16778277.001).
  • [ISSN] 0012-3692
  • [Journal-full-title] Chest
  • [ISO-abbreviation] Chest
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Contrast Media; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


57. Szkorupa M, Klein J, Bohanes T, Neoral C, Chudácek J: [Solitary fibrous tumor of pleural cavity]. Rozhl Chir; 2010 Dec;89(12):750-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary fibrous tumor of pleural cavity].
  • [Transliterated title] Solitární fibrózní tumor pleurální dutiny.
  • INTRODUCTION: Solitary fibrous pleural tumor (SFT) is, in most cases, a benign tumor arising from mesenchymal cells.
  • A malignant version of the tumor is rare and its histopathological evaluation is quite difficult.
  • Usually, SFT affects visceral, as well as parietal pleura, most commonly in a form of a pedunculated tumor.
  • Adjuvant therapy is indicated in malignant varieties of the tumor, however, its outcome is uncertain.
  • SUBJECTS AND METHODS: The authors present a group of 11 patients with solitary fibrous pleural tumors, who were operated at the Ist Faculty Hospital Surgical Clinic of the LF UP (Medical Faculty of the Palacky University) in Olomouc from 2006 to 2009.
  • CONCLUSION: Solitary pleural tumors are fairly rare tumors arising from fibroblastic cells, Its biological characteristics is uncertain and, in some cases, is difficult to assess based on immunohistochemical, as well as morphological indicators.
  • The treatment is surgical--removal of the tumor as far as the healthy tissue.
  • Adjuvant therapy is indicated in malignant varieties of the tumor.
  • SFT relaps rate is fairly high, depending on the tumor biological characteristics and its morphological features.
  • [MeSH-major] Pleural Neoplasms. Solitary Fibrous Tumor, Pleural

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21404515.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


58. Balduyck B, Lauwers P, Govaert K, Hendriks J, De Maeseneer M, Van Schil P: Solitary fibrous tumor of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report. J Thorac Oncol; 2006 Jul;1(6):588-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report.
  • Tumor-associated hypoglycemia as a paraneoplastic phenomenon is a well-known entity and is referred to as Doege-Potter syndrome.
  • All investigations proved to be normal, except for a chest x-ray, which showed a large pleural mass.
  • On transthoracic puncture, a tumor of pleural origin was diagnosed.
  • This tumor, presenting as a large, well-circumscribed encapsulated mass, was removed by thoracotomy.
  • On pathologic examination, the diagnosis of a solitary fibrous tumor with benign characteristics was made.
  • Solitary fibrous tumors are localized tumors of the pleura with an unpredictable behavior.
  • [MeSH-major] Neoplasms, Fibrous Tissue / pathology. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / pathology. Pleural Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Aged. Biopsy, Needle. Bronchoscopy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Radiography, Thoracic. Thoracotomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Potter syndrome.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409923.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Liu J, He JX, Cai CJ, Chen HZ, Wei B, Shao WL, Li SB: [The analysis on the misdiagnosis of solitary fibrous tumor of the pleura]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun;33(6):432-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The analysis on the misdiagnosis of solitary fibrous tumor of the pleura].
  • OBJECTIVE: To report the characteristics of solitary fibrous tumor of the pleura (SFTP), and to analyze the factors associated with the misdiagnosis of this disease.
  • RESULTS: The preoperative diagnosis was pleural mesothelioma in 7 cases, neurogenic tumor in 6, lung cancer in 4, SFTP in 2, hilar lymph node tuberculosis in 1 and inflammatory granuloma in 1 case.
  • All the cases underwent radical resection, and postoperative pathology and immunohistochemical study were performed, and the diagnosis of benign solitary fibrous tumor of the pleura was confirmed.
  • CONCLUSION: The recognition of the clinical characteristics of pleural solitary fibrous tumor is essential for improving the diagnosis of this uncommon disease.
  • [MeSH-major] Diagnostic Errors. Pleural Neoplasms / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979815.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


60. Casanova Espinosa A, Cisneros Serrano C, Girón Moreno RM, Olivera MJ, Moreno Balsalobre R, Zamora García E: [Pleural empyema associated with endobronchial lipoma]. Arch Bronconeumol; 2005 Mar;41(3):172-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleural empyema associated with endobronchial lipoma].
  • [Transliterated title] Empiema pleural asociado a lipoma endobronquial.
  • Bronchial benign tumors comprise fewer than 4% of pulmonary neoplasms.
  • Endobronchial lipoma is an extremely rare benign neoplasm accounting for only 0.1% to 0.5% of all lung tumors.
  • Clinical symptoms of lipoma depend on the location of the tumor, the severity of bronchial obstruction, and the functional and anatomical effects on the parenchyma distal to the obstruction.
  • Computed axial tomography usually reveals the adipose composition of the lipomatous tumor.
  • We report the case of an 83-year-old man diagnosed with community-acquired pneumonia that led to complications: pleural empyema caused by Haemophilus influenzae infection and atelectasis of the right middle and lower lobes secondary to a lipomatous endobronchial obstruction.
  • [MeSH-major] Bronchial Neoplasms / complications. Empyema, Pleural / etiology. Lipoma / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15766470.001).
  • [ISSN] 0300-2896
  • [Journal-full-title] Archivos de bronconeumología
  • [ISO-abbreviation] Arch. Bronconeumol.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


61. Stević R, Jovanović D, Mandarić M, Pesut D, Masulović D, Stosić-Opinćal T, Adzić T, Vasić N: [Radiologic manifestation of primary pleural tumors]. Acta Chir Iugosl; 2009;56(4):63-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiologic manifestation of primary pleural tumors].
  • OBJECTIVES: To show the radiological manifestations of primary pleural tumors.
  • PATIENTS AND METHODS: we carried out a retrospective analysis of radiological findings in 62 patients with primary malignant tumor of pleura.
  • Malignant tumors were present in 92.7% of the patients and benign ones in 7.2%.
  • The most common malignant tumor was mesothelioma (85.4%), and solitary fibrous tumor prevailed among benign tumors (9.7%).
  • Diffuse malignant mesothelioma manifested on computed tomography (CT) as a pleural thickening and effusion in 67.4% of the patients, tumors and effusion in 11.7%, and only as an effusion in 9.8% cases.
  • Thickening of the pleura appeared diffuse in 54% of patients and most often it had nodular pattern.
  • Both localized malignant and all benign tumors presented as tumor-like changes with the signs of necrosis in 50%.
  • CONCLUSION: The imaging methods have a key role in the diagnosis of pleural tumors.
  • CT shows different morphologic features of pleural lesions that have been established as a useful tool for differentiating malignant from benign disease.
  • However, magnetic resonance is preferred imaging method for assessing the extent and resectability of pleural tumors.
  • [MeSH-major] Pleural Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20419999.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] srp
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


62. Kristensen PL, Petersen RH, Hansen PB: [Spontaneous hemothorax from a fibrous pleural tumour in an expectant father. Is the delivery room a dangerous place for men?]. Ugeskr Laeger; 2007 Apr 2;169(14):1325-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Spontaneous hemothorax from a fibrous pleural tumour in an expectant father. Is the delivery room a dangerous place for men?].
  • [Transliterated title] Spontan haemothorax fra en fibrøs pleural tumor hos en vordende far. Er fødestuer farlige for maend?
  • An X-ray of the chest showed a tumour in the left side of the mediastinum and a large left pleural effusion.
  • During the operation a benign solitary fibrous tumour was radically resected from the pleura and a large hemothorax was removed.
  • This unusual presentation with severe bleeding from a pleural tumour was most probably initiated by the expectant father's excitement during his wife's labour.
  • [MeSH-major] Hemothorax / etiology. Neoplasms, Fibrous Tissue / complications. Pleural Neoplasms / complications
  • [MeSH-minor] Adult. Age of Onset. Diagnosis, Differential. Emotions. Fathers / psychology. Humans. Male. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17437697.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


63. Li W, Ni Y, Tu Z, Wu S, Wu Z, Zheng S: Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance. Eur J Cardiothorac Surg; 2009 Sep;36(3):460-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Study of telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer and its clinical significance.
  • OBJECTIVE: To detect telomerase activity in pleural lavage fluid specimens in patients with non-small-cell lung cancer (NSCLC) and to evaluate its clinical value.
  • METHODS: From July 2005 to May 2007, 167 pleural lavage fluid specimens were obtained from 135 patients with NSCLC and 32 patients with benign lung tumour during operation.
  • Pleural lavage cytology (PLC) analysis of the pleural lavage fluid specimens was used for comparison.
  • RESULTS: The positive rate of telomerase activity and PLC in pleural lavage fluid from patients with NSCLC was 25.2% (34/135) and 8.1% (11/135), respectively, with a significant difference (P<0.05).
  • Telomerase activity was negative in all 32 patients with benign lung tumour.
  • There was a significant relationship between telomerase activity and pleural extension, T level, N level as well as the clinical TNM (tumour, node, metastasis) stage of lung cancer.
  • CONCLUSION: Telomerase activity is a useful adjunct for cytological method in the diagnosis of pleural micro-metastasis and was related to prognosis in a patient with NSCLC.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Pleural Cavity / enzymology. Pleural Neoplasms / secondary. Telomerase / metabolism
  • [MeSH-minor] Adult. Aged. Clinical Enzyme Tests / methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Analysis. Therapeutic Irrigation

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502078.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


64. Creaney J, Robinson BW: Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med; 2009 Jul;15(4):366-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum and pleural fluid biomarkers for mesothelioma.
  • PURPOSE OF REVIEW: Malignant mesothelioma is an asbestos-induced, aggressive tumour.
  • In centres across the world, research has focused on evaluating biomarkers for malignant mesothelioma screening, diagnosis, prognostication and monitoring.
  • The assay sensitivity ranges from 50% at diagnosis to 84% in advanced disease.
  • The assay has a high level of specificity relative to benign lung and pleural conditions and is positive in 10-15% of other malignancies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis
  • [MeSH-minor] GPI-Linked Proteins. Humans. Membrane Glycoproteins / metabolism. Osteopontin / metabolism. Pleural Cavity / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19417672.001).
  • [ISSN] 1531-6971
  • [Journal-full-title] Current opinion in pulmonary medicine
  • [ISO-abbreviation] Curr Opin Pulm Med
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  • [Number-of-references] 52
  •  go-up   go-down


65. Toda K, Takahashi J, Tabuchi Y, Koizumi T, Nishimura R, Nishio W, Tsubota N, Matsuoka H: Clinical usefulness of CEA-mRNA determination in minor effusion. J Exp Clin Cancer Res; 2005 Sep;24(3):423-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant pleural effusion of lung cancer is an important prognostic factor, even in minor effusions.
  • Previous studies reported that cytological examination could not detect malignant cells in pleural dissemination cases.
  • The subjects were selected from 132 primary lung cancer patients and 8 benign tumor patients as negative control.
  • These subjects had no apparent pleural effusion or distant metastasis.
  • [MeSH-major] Carcinoembryonic Antigen / genetics. Pleural Effusion, Malignant / metabolism. RNA, Messenger / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270529.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / DNA Primers; 0 / RNA, Messenger; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases
  •  go-up   go-down


66. Cho SW, Marsh JW, Steel J, Holloway SE, Heckman JT, Ochoa ER, Geller DA, Gamblin TC: Surgical management of hepatocellular adenoma: take it or leave it? Ann Surg Oncol; 2008 Oct;15(10):2795-803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatocellular adenoma (HA) is a rare benign tumor of the liver.
  • Surgical morbidities included pleural effusion requiring percutaneous drainage (n = 2), pneumonia (n = 1), and wound infection (n = 1).

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18696154.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K12 HD 049109
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


67. Kaur H, Bagga R, Saha SC, Gainder S, Srinivasan R, Adhya AK, Dhaliwal LK: Juvenile granulosa cell tumor of the ovary presenting with pleural effusion and ascites. Int J Clin Oncol; 2009 Feb;14(1):78-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile granulosa cell tumor of the ovary presenting with pleural effusion and ascites.
  • Juvenile granulosa cell tumor (GCT) is a rare tumor, and the majority (90%) are reported in the prepubertal or under-30-year age group, in contrast to the adult type, which is more common in the fifth decade.
  • Being solid tumors, they may be associated with ascites and pleural effusion (Meigs' syndrome), which resolve after surgical removal of the tumor.
  • Tumor markers for GCT are still investigational (inhibin) and of not much use in making a preoperative diagnosis, unlike in the case of germ cell tumors.
  • In the present patient, because of the association of Meigs' syndrome, a preoperative diagnosis of benign tumors such as fibroma/thecoma was also considered.
  • We report this rare tumor with an aim of reviewing the diagnosis and management from the reported literature.
  • [MeSH-major] Ascites / etiology. Granulosa Cell Tumor / pathology. Meigs Syndrome / pathology. Ovarian Neoplasms / pathology. Pleural Effusion, Malignant / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Singapore Med J. 2001 May;42(5):203-7 [11513057.001]
  • [Cites] Korean J Intern Med. 2005 Mar;20(1):105-9 [15906965.001]
  • [Cites] Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):323-7 [9988794.001]
  • [Cites] Obstet Gynecol. 1978 Dec;52(6):718-23 [733139.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):51-5 [10094880.001]
  • [Cites] Gynecol Oncol. 1995 Dec;59(3):405-8 [8522265.001]
  • [Cites] Gynecol Oncol. 2007 Feb;104(2):396-400 [17030354.001]
  • [Cites] Cancer. 1997 May 15;79(10):1951-5 [9149022.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):204-9 [15589602.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):35-41 [10094877.001]
  • [Cites] Am J Obstet Gynecol. 2004 Jul;191(1):366-7 [15295395.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):484-8 [8774662.001]
  • [Cites] N Engl J Med. 1989 Sep 21;321(12):790-3 [2770810.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):338-44 [7705666.001]
  • [Cites] Gynecol Oncol. 2006 Oct;103(1):31-4 [16537089.001]
  • (PMID = 19225930.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Tamura Y, Kushibe K, Tojo T, Takahama M, Kimura M, Taniguchi S: Intralobar sequestration presenting as a large intrapulmonary hematoma and massive hemothorax. Jpn J Thorac Cardiovasc Surg; 2006 Oct;54(10):437-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • His chest computed tomography (CT) scan revealed a large intrapulmonary hematoma and massive hemothorax, mimicking a benign lung tumor ruptured into the pleural cavity.
  • We should keep the possibility of this anomaly in mind if a patient with hemoptysis has a cystic lung tumor and hemothorax on CT scan.
  • [MeSH-major] Bronchopulmonary Sequestration / diagnosis. Hematoma / etiology. Hemothorax / etiology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Lung Neoplasms / diagnosis. Male. Radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 1979 Feb;34(1):96-101 [442005.001]
  • [Cites] Pediatr Radiol. 1980 Sep;10 (1):54-6 [7422394.001]
  • [Cites] Scand J Thorac Cardiovasc Surg. 1983;17(2):177-9 [6612259.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Sep;126(3):872-3 [14502174.001]
  • [Cites] Chest. 1994 Sep;106(3):954-5 [8082388.001]
  • [Cites] Curr Probl Surg. 1986 Apr;23(4):245-314 [3709214.001]
  • [Cites] N Y State J Med. 1974 Jun;74(6):961-2 [4525983.001]
  • [Cites] J Thorac Cardiovasc Surg. 1974 Oct;68(4):673-4 [4528695.001]
  • (PMID = 17087324.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


69. Alberti N, Serrano-Egea A, García-García E, Ballestín C, Pérez-Barrios A, López-Ríos F, de Agustín P: Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry. Acta Cytol; 2007 Mar-Apr;51(2):203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary papillary serous carcinoma of the peritoneum: report of a case with diagnosis by fine needle aspiration and immunocytochemistry.
  • BACKGROUND: Primary papillary serous carcinoma (PPSC) of the peritoneum is a rare neoplasm, histologically indistinguishable from papillary serous carcinoma of the ovary, which diffusely involves the peritoneum but spares or minimally invades the ovaries.
  • To the best of our knowledge, the preoperative and the fine needle aspiration diagnosis of this disorder have not been reported before.
  • CASE: A woman developed an extensive peritoneal neoplasm 4 years after hysterectomy and bilateral salpingo-oophorectomy for benign disease.
  • Fine needle aspiration of the tumor was performed, and the cytologic and immunocytochemical findings were consistent with papillary serous carcinoma.
  • A diagnosis of PPSC of the peritoneum was rendered because review of all slides from previous surgical specimens showed no evidence of carcinoma and no other primary tumors were found elsewhere.
  • CONCLUSION: Fine needle aspiration cytology coupled with immunocytochemical and clinical data allows an unequivocal preoperative diagnosis of papillary serous carcinoma (primary peritoneal or with an ovarian origin).
  • Based on this fact, the preoperative fine needle aspiration cytology diagnosis of PSCP should be restricted to oophorectomized patients.
  • [MeSH-major] Cystadenocarcinoma, Papillary / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / etiology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / biosynthesis. Biopsy, Fine-Needle / methods. Diagnosis, Differential. Female. Humans. Hysterectomy. Immunohistochemistry / methods. Middle Aged. Pleural Effusion, Malignant / etiology. Pleural Effusion, Malignant / pathology. Predictive Value of Tests. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17425204.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Huang F, Wang XL, Yang L, Yin BX, Geng Y, Li TT: [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2008 Apr;24(4):370-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of combined determination of serum and pleural effusion level of CEA,CYFRA21-1, TPS in the diagnosis of lung cancer].
  • AIM: To study the clinical value of combined determination of carcinoembryonic antigen (CEA), cytokeratin-19-fragments (CYFRA21-1) and tissue polypeptide specific antigen (TPS) levels in both serum and pleural effusion in the diagnosis of lung cancer.
  • METHODS: The levels of CEA, CYFRA21-1 and TPS in serum and pleural effusion were measured in 78 patients with lung cancer and 45 patients with benign lung disease by using electrochemiluminescence and ELISA methods respectively.
  • RESULTS: The levels of CEA, CYFRA21-1 and TPS in pleural effusion of patients with lung cancer were much higher than those with benign lung disease (P<0.01).
  • The levels of CEA and TPS in serum of patients with lung cancer were much higher than those with benign lung disease (P<0.05, P<0.01).
  • It was also found that the levels of these tumor markers in pleural effusion were higher and more sensitive than those in sera, especially TPS.
  • TPS showed the highest sensitivity in single tumor marker detection, and TPS+CYFRA21-1+ CEA showed the highest sensitivity and accuracy in combined tumor marker detection for diagnosis of lung cancer in pleural effusion.
  • CONCLUSION: The combined detection of CEA, CYFRA21-1 and TPS in pleural effusion showed higher sensitivity, better accuracy and higher clinical value than those in serum for diagnosis of lung cancer.
  • [MeSH-major] Antigens, Neoplasm / blood. Antigens, Neoplasm / metabolism. Carcinoembryonic Antigen / blood. Carcinoembryonic Antigen / metabolism. Keratin-19 / blood. Keratin-19 / metabolism. Lung Neoplasms / diagnosis. Peptides / blood. Pleural Effusion / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18394347.001).
  • [ISSN] 1007-8738
  • [Journal-full-title] Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  • [ISO-abbreviation] Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Carcinoembryonic Antigen; 0 / Keratin-19; 0 / Peptides; 0 / antigen CYFRA21.1; 0 / tissue polypeptide specific antigen
  •  go-up   go-down


71. Albert A, Tarrado X, Montaner A, Cáceres F, Parareda A, Cruz O, Mora J, Morales L: [The role of surgery for lung nodules in pediatric oncology]. Cir Pediatr; 2006 Oct;19(4):228-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] La cirugía de los nódulos pulmonares en oncología pediátrica.
  • The primary pathological diagnoses include: Osteosarcoma n = 17, Ewing's sarcoma n = 14, Rhabdomyosarcoma n = 5, Germ cell tumor n = 4, other sarcomas n = 4, Wilms' tumor n = 3, Neuroblastoma n = 3, Lymphoma n = 2.
  • Twenty-nine cases had lung nodules at diagnosis; in 20 they were found during therapy; in 29 concomitant with other sites of relapse off therapy; and in 16 patients as an isolated event during follow-up.
  • Fifty-five biopsy procedures were performed through thoracotomy, thoracoscopy or pleural effusion cytology.
  • Among the nine, five showed either normal lung tissue or scarring after tumor necrosis, and four had other benign diagnoses including: reactive inflammatory cells, pleural lymphangioma, mycobacteria infection and inflammatory pseudotumor.
  • In 39 instances biopsy was not done either because the diagnosis could be made through specific tests, or because the nodules disappeared in a follow-up CT scan within 2 weeks, or because of disease progressing in spite of treatment.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17352112.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


72. Soyer T, Karnak I, Ciftci AO, Senocak ME, Tanyel FC, Büyükpamukçu N: The results of surgical treatment of chest wall tumors in childhood. Pediatr Surg Int; 2006 Feb;22(2):135-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The diagnosis was malignant tumor in 12 (70%) and benign in 5 (30%).
  • They were Ewing's sarcoma (ES) (n = 4), primitive neuroectodermal tumor (PNET) (n = 3), Askin's tumor (n = 1), rhabdomyosarcoma (RMS) (n = 2), neuroblastoma (n = 2), osteochondroma (n = 1), aneurysmal bone cyst (n = 2) and hamartoma (n = 2).
  • Preoperative chemotherapy was given to most patients with malignant tumor.
  • All patients had only local tumor at the time of resection.
  • All tumor tissues with the affected rib/ribs were resected en bloc with the adjacent tissues.
  • Wound infection and pleural fistula occurred in one patient.
  • Patients with benign tumor were free of complaints or complications during follow up.
  • All patients with malignant tumor received postoperative chemotherapy.
  • Since most of the CWT are malignant and not initially suitable for surgical excision, the management includes tissue diagnosis either by tru-cut or open biopsy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Pediatr Surg. 1994 Nov;3(4):267-76 [7850367.001]
  • [Cites] Spine (Phila Pa 1976). 1985 Sep;10 (7):618-22 [4071270.001]
  • [Cites] J Pediatr Surg. 1977 Dec;12(6):991-9 [201742.001]
  • [Cites] J Pediatr Surg. 1980 Dec;15(6):906-12 [7463293.001]
  • [Cites] Plast Reconstr Surg. 1996 Oct;98(5):804-10 [8823018.001]
  • [Cites] J Pediatr Surg. 1999 Dec;34(12):1773-8 [10626852.001]
  • [Cites] Ann Thorac Surg. 1988 Jul;46(1):40-4 [3382285.001]
  • [Cites] J Pediatr Surg. 1988 Jul;23(7):667-73 [3204468.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jun;119(6):1154-61 [10838532.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Mar;117(3):588-91; discussion 591-2 [10047664.001]
  • [Cites] J Spinal Disord. 1994 Dec;7(6):522-7 [7873852.001]
  • [Cites] J Pediatr Surg. 1978 Jun;13(3):275-80 [209164.001]
  • [Cites] J Pediatr Surg. 1994 Sep;29(9):1189-91 [7807342.001]
  • (PMID = 16328338.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


73. Shi YC, Tang LF, Chen ZM, Du LZ: Pleuropulmonary blastoma in an infant. Indian J Pediatr; 2009 Sep;76(9):948-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The mass was removed completely by left upper lobectomy and histology confirmed diagnosis of type III PPB.
  • The immature blastematous tissue was positive for vimentin while benign epithelium was positive for epithelial membrane antigen and cytokeratin.
  • No lymph nodule metastasis was found in the 7 lymph nodules obtained from the hilum of the lung near the tumor.
  • [MeSH-major] Lung Neoplasms / pathology. Pleural Neoplasms / pathology. Pulmonary Blastoma / pathology


74. Passebosc-Faure K, Li G, Lambert C, Cottier M, Gentil-Perret A, Fournel P, Pérol M, Genin C: Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions. Clin Cancer Res; 2005 Oct 1;11(19 Pt 1):6862-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of a panel of molecular markers for the diagnosis of malignant serous effusions.
  • EXPERIMENTAL DESIGN: One hundred fourteen serous effusions from 71 patients with tumors and 43 patients with benign diseases were subjected to RT-PCR for expression of carcinoembryonic antigen (CEA), epithelial cell adhesion molecule (Ep-CAM), E-cadherin, mammaglobin, mucin 1 (MUC1) isoforms MUC1/REP, MUC1/Y, and MUC1/Z, calretinin, and Wilms' tumor 1 susceptibility gene.
  • CONCLUSIONS: A combination of cytology and RT-PCR analysis of CEA and Ep-CAM significantly improved the detection sensitivity of tumor cells in serous effusions.
  • RT-PCR analysis of CEA, Ep-CAM, and mammaglobin in serous effusions could be a beneficial adjunct to cytology for the diagnosis of malignancy.
  • [MeSH-major] Biomarkers, Tumor. Genetic Predisposition to Disease. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Aged. Antigens / biosynthesis. Antigens, Neoplasm / biosynthesis. Ascites / metabolism. Cadherins / biosynthesis. Calbindin 2. Carcinoembryonic Antigen / biosynthesis. Carcinoma / metabolism. Cell Adhesion Molecules / biosynthesis. Cell Line, Tumor. DNA Primers / chemistry. Female. Genes, Wilms Tumor. Glycoproteins / biosynthesis. Humans. Male. Mammaglobin A. Middle Aged. Mucin-1. Mucins / biosynthesis. Neoplasm Proteins / biosynthesis. Oligonucleotides, Antisense / chemistry. Pleural Effusion. RNA / metabolism. Reverse Transcriptase Polymerase Chain Reaction. S100 Calcium Binding Protein G / biosynthesis. Sensitivity and Specificity. Uteroglobin / biosynthesis. WT1 Proteins / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16203775.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Cadherins; 0 / Calbindin 2; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / DNA Primers; 0 / EPCAM protein, human; 0 / Glycoproteins; 0 / MUC1 protein, human; 0 / Mammaglobin A; 0 / Mucin-1; 0 / Mucins; 0 / Neoplasm Proteins; 0 / Oligonucleotides, Antisense; 0 / S100 Calcium Binding Protein G; 0 / SCGB2A2 protein, human; 0 / WT1 Proteins; 63231-63-0 / RNA; 9060-09-7 / Uteroglobin
  •  go-up   go-down


75. Kachali C, Eltoum I, Horton D, Chhieng DC: Use of mesothelin as a marker for mesothelial cells in cytologic specimens. Semin Diagn Pathol; 2006 Feb;23(1):20-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine were benign effusions, 11 mesotheliomas, and 18 metastatic adenocarcinomas.
  • Mesothelin staining was positive in 7/9 benign cases, 8/11 mesotheliomas, and 8/18 adenocarcinomas.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Membrane Glycoproteins / metabolism. Mesothelioma / diagnosis
  • [MeSH-minor] Ascitic Fluid / pathology. Calbindin 2. Female. GPI-Linked Proteins. Humans. Immunohistochemistry. Male. Middle Aged. Pleural Effusion / pathology. S100 Calcium Binding Protein G / metabolism. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044192.001).
  • [ISSN] 0740-2570
  • [Journal-full-title] Seminars in diagnostic pathology
  • [ISO-abbreviation] Semin Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / S100 Calcium Binding Protein G; 0 / mesothelin
  •  go-up   go-down


76. Szczepulska-Wójcik E, Langfort R, Roszkowski-Sliz K: [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation]. Pneumonol Alergol Pol; 2007;75(1):57-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
  • INTRODUCTION: Histopathological diagnosis of malignant mesothelioma (MM) and differentiating it from tumors infiltrating the pleura is very difficult.
  • Distinguishing benign reactive mesothelial cell proliferation from MM also presents problems.
  • The objective of this study was to evaluate the significance of selected immunohistochemical stains in differentiating MM from non-small cell lung cancers infiltrating the pleura and from benign reactive mesothelial cell proliferation.
  • MATERIAL AND METHODS: The material encompassed 86 cases of MM, 54 cases of NSCLC infiltrating the pleura, and 43 cases of benign reactive mesothelial cell proliferation.
  • Non-small cell lung cancers infiltrating the pleura: Coexpression of cytokeratin and vimentin was found in 17.6% of the cases, positive staining of membranes for EMA, in 13% cases.
  • Benign reactive mesothelial cell proliferation: Protein p53 was present in 9.3% of cases, whereas no positive staining for EMA was found.
  • In the diagnosis of spindle-cell pleural tumors and the fibrous form of MM and benign reactive mesothelial cell proliferation , markers of mesothelial cells are noncontributory.
  • Immunohistochemical staining fails to identify a reactive process, but a diffuse, positive stain for EMA and the presence of protein p53 support the diagnosis of MM.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / analysis. Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / pathology. Mesothelioma / pathology. Neoplasm Proteins / analysis. Neoplasms, Mesothelial / pathology. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Antibodies, Monoclonal / analysis. Diagnosis, Differential. Epithelium / chemistry. Epithelium / pathology. Female. Humans. Hyperplasia / pathology. Immunohistochemistry. Lung / chemistry. Lung / pathology. Male. Middle Aged. Pleura / chemistry. Pleura / pathology. Pleural Effusion / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17541913.001).
  • [ISSN] 0867-7077
  • [Journal-full-title] Pneumonologia i alergologia polska
  • [ISO-abbreviation] Pneumonol Alergol Pol
  • [Language] pol
  • [Publication-type] Comparative Study; English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


77. Cardinale L, Ardissone F, Garetto I, Marci V, Volpicelli G, Solitro F, Fava C: Imaging of benign solitary fibrous tumor of the pleura: a pictorial essay. Rare Tumors; 2010;2(1):e1
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of benign solitary fibrous tumor of the pleura: a pictorial essay.
  • Solitary fibrous tumor of the pleura (SFTP) is a mesenchymal tumor that tends to involve the pleura, and is also described in other thoracic and extrathoracic sites.
  • SFTP usually presents as a peripheral mass abutting the pleural surface, to which it is attached by a broad base or by a pedicle that allows it to be mobile.
  • SFTPs exist in benign and malignant forms.
  • A precise pre-operative diagnosis can be arrived at with a cutting-needle biopsy, although most cases are diagnosed with postoperative histology and immunohistochemical analysis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139938.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994496
  • [Keywords] NOTNLM ; computed tomography / pleura / solitary fibrous tumor of the pleura / tumor / ultrasonography
  •  go-up   go-down


78. Davidson B, Baekelandt M, Shih IeM: MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells. Diagn Cytopathol; 2007 Dec;35(12):756-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OC/PPC effusions (n = 142) and benign reactive effusions (n = 10) were immunostained for MUC4 expression.
  • Immunoreactivity was scored in carcinoma cells and RMC and was compared with tumor cell expression in 60 previously studied primary carcinomas and solid metastases and analyzed for association with clinicopathologic parameters, including survival.
  • MUC4 was detected in carcinoma cells in 141/142 (99%) effusions, with comparable expression in peritoneal and pleural effusions.
  • The data in the present study, together with our earlier report, show that MUC4 is an excellent marker for differentiating OC/PPC from both benign and malignant mesothelial cells.
  • [MeSH-major] Ascitic Fluid / metabolism. Cystadenocarcinoma, Serous / metabolism. Mesothelioma / metabolism. Mucins / biosynthesis. Ovarian Neoplasms / metabolism. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Age Factors. Biomarkers, Tumor / analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mucin-4. Oligonucleotide Array Sequence Analysis. Peritoneal Neoplasms / metabolism. Peritoneal Neoplasms / pathology. Up-Regulation

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 18008338.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4; 0 / Mucins
  •  go-up   go-down


79. Cristaudo A, Foddis R, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Canessa PA, Chella A, Lucchi M, Mussi A, Mutti L: Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma. Int J Biol Markers; 2010 Jul-Sep;25(3):164-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison between plasma and serum osteopontin levels: usefulness in diagnosis of epithelial malignant pleural mesothelioma.
  • BACKGROUND: A potential role of serum osteopontin (OPN) and serum mesothelin-related peptide (SMRP) in the diagnosis of malignant pleural mesothelioma (MPM) has been recently reported.
  • Our study aimed to evaluate the influence of preanalytic variables on serum and plasma OPN, to compare serum and plasma OPN in the same population, and to assess whether OPN levels can aid in the diagnostic distinction of patients with MPM versus benign respiratory disease (BRD) and healthy subjects exposed to asbestos.
  • Plasma and serum OPN may be useful markers in the diagnosis of epithelial MPM in addition to traditional radiological exams.
  • [MeSH-major] Asbestos / adverse effects. Biomarkers, Tumor / blood. Mesothelioma / blood. Osteopontin / blood. Pleural Neoplasms / blood. Specimen Handling

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • Biospecimen Research Database. Biospecimen Research Database .
  • Hazardous Substances Data Bank. ASBESTOS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878622.001).
  • [ISSN] 1724-6008
  • [Journal-full-title] The International journal of biological markers
  • [ISO-abbreviation] Int. J. Biol. Markers
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 106441-73-0 / Osteopontin; 1332-21-4 / Asbestos
  •  go-up   go-down


80. Robinson LA: Solitary fibrous tumor of the pleura. Cancer Control; 2006 Oct;13(4):264-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura.
  • BACKGROUND: The solitary fibrous tumor of the pleura (SFTP) is a rare primary tumor arising from mesenchymal cells in the areolar tissue subjacent to the mesothelial-lined pleura.
  • The tumor appears to be unrelated to malignant pleural mesothelioma, the most common primary tumor of the pleura.
  • METHODS: In just over half of these cases, the neoplasm presents as an asymptomatic mass, is often quite large, and is benign in 78% to 88% of patients.
  • The initial evaluation and diagnosis, tumor classification, surgical treatment, results of therapy, and long-term prognosis are reviewed, based on a selective review of the literature from MEDLINE beginning 1980.
  • RESULTS: Complete en bloc surgical resection is the preferred treatment of benign and malignant varieties of the tumor.
  • The pedunculated tumors attached to the visceral pleura can be effectively treated with a wedge resection of lung.
  • CONCLUSIONS: Benign SFTP has a high cure rate and an 8% local recurrence rate that is usually amenable to curative re-excision.
  • The majority of patients with recurrent disease die of the tumor within 2 years.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Neoplasms, Fibrous Tissue / therapy. Pleural Neoplasms / diagnosis. Pleural Neoplasms / therapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Incidence. Neoadjuvant Therapy. Thoracic Surgical Procedures. Tomography, X-Ray Computed. United States / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17075563.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


81. Chatti K, Nouira K, Ben Reguigua M, Bedioui H, Oueslati S, Laabidi B, Alaya M, Ben Abdallah N: [Solitary fibrous tumor of the pancreas. A case report]. Gastroenterol Clin Biol; 2006 Feb;30(2):317-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Solitary fibrous tumor of the pancreas. A case report].
  • [Transliterated title] Tumeur fibreuse solitaire du pancréas. A propos d'un cas.
  • Solitary fibrous tumour (SFT), a rare mesenchymal neoplasm usually arising from the pleura, may also occur in many other extra pleural sites.
  • This report describes the case of a benign SFT of the pancreas occurring in a 41-year-old man who presented with a solid epigastric mass.
  • Surgical resection of the tumour was performed, and the patient died from postoperative complications.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565671.001).
  • [ISSN] 0399-8320
  • [Journal-full-title] Gastroentérologie clinique et biologique
  • [ISO-abbreviation] Gastroenterol. Clin. Biol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


82. Tessmer CS, Barcellos FC, Falchi LC: Pseudo-Meigs' syndrome associated to renal pelvis tumor. Int Braz J Urol; 2005 May-Jun;31(3):256-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudo-Meigs' syndrome associated to renal pelvis tumor.
  • INTRODUCTION: Pseudo-Meigs' syndrome is associated with tumors different from the benign ovary tumor, but it has never been described in association to transitional cell carcinoma.
  • CASE REPORT: A female 73 year-old patient presenting pleural effusion nonmetastatic associated with renal pelvis transitional cell carcinoma that resolved and did not recur after radical nephroureterectomy.
  • Although being a rare clinical entity, the identification of such syndrome can result in an accurate diagnosis, leading to an efficient surgical treatment, without comorbidity for the patient.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15992429.001).
  • [ISSN] 1677-5538
  • [Journal-full-title] International braz j urol : official journal of the Brazilian Society of Urology
  • [ISO-abbreviation] Int Braz J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


83. Takagi M, Kuwano K, Watanabe K, Akiba T: A case of recurrence and rapid growth of pleural solitary fibrous tumor 8 years after initial surgery. Ann Thorac Cardiovasc Surg; 2009 Jun;15(3):178-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of recurrence and rapid growth of pleural solitary fibrous tumor 8 years after initial surgery.
  • A 69-year-old woman underwent resection of a solitary fibrous tumor (SFT) of the left pleura in April 1997 and of locally recurrent SFT in the left thoracic cavity in September 2003.
  • A postoperative follow-up chest CT scan in March 2005 revealed pleural thickening at two sites of the left thoracic cavity.
  • The two resected tumors were benign SFT, and were diagnosed as locally recurrent SFT in the left thoracic cavity.
  • It has been reported that despite its benign histopathology, pleural SFT recurs more than once after surgery, and the interval between recurrences tends to shorten from the second recurrence.
  • In this patient, the tumor recurred twice and showed a rapidly enlarging tendency at the time of the second recurrence, suggesting the need for careful follow-up at short intervals.
  • [MeSH-major] Neoplasm Recurrence, Local. Pleural Neoplasms / surgery. Pulmonary Surgical Procedures. Solitary Fibrous Tumor, Pleural / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597394.001).
  • [ISSN] 2186-1005
  • [Journal-full-title] Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia
  • [ISO-abbreviation] Ann Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


84. Demirag F, Unsal E, Tastepe I: Biphasic malignant mesothelioma cases with osseous differentiation and long survival: a review of the literature. Lung Cancer; 2007 Aug;57(2):233-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two male patients aged 66 and 54 years presented with chest pain, bloody pleural effusions, and diffuse and nodular pleural thickening.
  • Epithelioid tumor cells as well as benign osteoclasts within the ossification reacted positively for cytokeratin 5/6, whereas sarcomatoid areas were negative.
  • [MeSH-major] Mesothelioma / pathology. Ossification, Heterotopic. Pleural Neoplasms / pathology
  • [MeSH-minor] Aged. Asbestosis / complications. Asbestosis / pathology. Biomarkers, Tumor / metabolism. Follow-Up Studies. Humans. Immunohistochemistry. Keratin-5 / metabolism. Keratin-6 / metabolism. Male. Middle Aged. Osteoclasts / metabolism. Survival Analysis. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17363104.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HBME-1 antigen; 0 / Keratin-5; 0 / Keratin-6
  • [Number-of-references] 24
  •  go-up   go-down


85. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW: Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol; 2008 Aug;3(8):851-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: There is increasing interest in identifying a blood-based marker for the asbestos-related tumor, malignant mesothelioma.
  • The purpose of the current study was to directly compare these biomarkers in the same sample population, determining their sensitivity and specificity in establishing a diagnosis, and to determine if diagnostic accuracy for mesothelioma is improved by combining the data from all three markers.
  • METHODS: Serum levels of mesothelin, MPF and osteopontin were determined by commercially available assays in 66 samples from patients with pleural malignant mesothelioma, 20 healthy individuals, 21 patients with asbestos-related lung or pleural disease, 30 patients presenting with benign pleural effusions and 30 patients with other malignancies.
  • At a level of specificity of 95% relative to healthy controls and patients with benign asbestos related disease, the sensitivity for mesothelioma was 34% for MPF, 47% for osteopontin and 73% for mesothelin.
  • Osteopontin and MPF were unable to differentiate patients with mesothelioma from patients with other malignancies or those presenting with transudative pleural effusions.
  • CONCLUSION: Serum mesothelin remains the most specific marker for the diagnosis of mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / blood. Membrane Glycoproteins / blood. Mesothelioma / blood. Osteopontin / blood. Pleural Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Neoplasm / blood. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Prognosis. ROC Curve. Sensitivity and Specificity. Survival Rate

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18670302.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


86. Husain AN, Colby TV, Ordóñez NG, Krausz T, Borczuk A, Cagle PT, Chirieac LR, Churg A, Galateau-Salle F, Gibbs AR, Gown AM, Hammar SP, Litzky LA, Roggli VL, Travis WD, Wick MR: Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med; 2009 Aug;133(8):1317-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
  • CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose.
  • OBJECTIVE: To develop practical guidelines for the pathologic diagnosis of MM.
  • CONCLUSIONS: There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM.
  • Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory.
  • [MeSH-major] Mesothelioma / diagnosis. Peritoneal Neoplasms / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19653732.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Practice Guideline
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 53
  •  go-up   go-down


87. Akata S, Yoshimura M, Nishio R, Park J, Saito K, Uchida O, Ohira T, Kato H, Okada S, Kakizaki D: High-resolution computed tomographic findings of small peripherally located squamous cell carcinoma. Clin Imaging; 2008 Jul-Aug;32(4):259-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the spread of high-resolution computed tomography (HRCT) screening for lung cancer, we are increasingly faced with the need to determine whether certain small lesions are benign or malignant.
  • HRCT findings of all 27 cases were analyzed retrospectively and independently by three radiologists who were unaware of the pathological diagnosis, and decisions were reached by consensus with special attention to 10 review points.
  • Tumor margin features included spiculation, notching, irregularity, and ground-glass opacity.
  • Surrounding structural features consisted of pleural indentation, pulmonary emphysema, and satellite lesions.
  • The presence of irregularity (70.4%), surrounding pulmonary emphysema (70.4%), and pleural indentation (51.9%) was observed frequently.
  • HRCT images of peripherally located squamous cell carcinoma suggested that the demonstration of irregularity, surrounding pulmonary emphysema, pleural indentation, and absence of calcification may contribute to the accurate CT diagnosis of small peripheral squamous cell carcinoma.


88. Neumann V, Löseke S, Tannapfel A: [Medical insurance aspects of peritoneal tumors with particular attention to peritoneal mesotheliomas]. Med Klin (Munich); 2009 Oct 15;104(10):765-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant peritoneal mesotheliomas arise mainly in male patients and the median age of initial diagnosis is about 56 years.
  • Asbestos exposure is the best-known and most common risk factor associated with the development of both pleural and peritoneal mesotheliomas and, therefore, about 90% of cases can be assessed as asbestos-associated.
  • Patients with peritoneal mesotheliomas have distinctly higher asbestos burden of the lungs than patients with pleural mesotheliomas.
  • The mean latency period between exposure and diagnosis of peritoneal mesothelioma ranges from 35 to 40 years and is comparable to that of pleural mesothelioma.
  • No significant evidence exists for the classification of well-differentiated papillary mesothelioma, solitary fibrous tumor, adenomatoid tumor, primary peritoneal serous borderline tumor, and benign multicystic mesothelioma as asbestos-associated tumors.
  • [MeSH-minor] Biopsy. Causality. Cross-Sectional Studies. Female. Germany. Humans. Insurance, Accident / legislation & jurisprudence. Insurance, Accident / statistics & numerical data. Male. Middle Aged. Peritoneum / pathology. Pleural Neoplasms / classification. Pleural Neoplasms / epidemiology. Pleural Neoplasms / etiology. Pleural Neoplasms / pathology. Risk Factors. Workers' Compensation / legislation & jurisprudence. Workers' Compensation / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Asbestos.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Ind Med. 1960 Oct;17:260-71 [13782506.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):403-6 [15737040.001]
  • [Cites] Environ Res. 1984 Dec;35(2):531-51 [6391911.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Dec;19(6):1067-87, vi [16325124.001]
  • [Cites] Am J Surg Pathol. 1990 Mar;14(3):230-9 [2305929.001]
  • [Cites] Ann Oncol. 2007 Jun;18(6):985-90 [17030547.001]
  • [Cites] Am J Surg Pathol. 1995 Oct;19(10):1124-37 [7573671.001]
  • [Cites] Am J Clin Oncol. 2008 Feb;31(1):49-54 [18376228.001]
  • [Cites] Br J Ind Med. 1983 May;40(2):145-52 [6299326.001]
  • [Cites] Q J Med. 1976 Jul;45(179):427-49 [948545.001]
  • [Cites] Am J Gastroenterol. 1981 Apr;75(4):311-3 [7258177.001]
  • [Cites] J Environ Pathol Toxicol Oncol. 1996;15(2-4):191-4 [9216805.001]
  • [Cites] Cancer. 1981 Jul 1;48(1):134-9 [7237380.001]
  • [Cites] Environ Health. 2008 Jan 24;7:4 [18218073.001]
  • [Cites] Histopathology. 1991 Dec;19(6):515-22 [1786936.001]
  • [Cites] Am J Respir Crit Care Med. 2008 Sep 15;178(6):624-9 [18556631.001]
  • [Cites] Ultrastruct Pathol. 2002 Nov-Dec;26(6):355-63 [12537760.001]
  • [Cites] Am J Ind Med. 1988;14(3):331-9 [3189349.001]
  • [Cites] Histopathology. 2008 Jun;52(7):824-30 [18494612.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):724-37 [15981812.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1304-9 [11688466.001]
  • [Cites] Int J Urol. 2008 Jun;15(6):560-1 [18489651.001]
  • [Cites] Chest. 1980 Feb;77(2):133-7 [7353405.001]
  • [Cites] Pathologe. 1999 May;20(3):169-76 [10412176.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):344-56 [7856747.001]
  • [Cites] Cancer. 1988 May 15;61(10):2019-21 [3282640.001]
  • [Cites] Am J Surg Pathol. 1988 Oct;12(10):737-46 [3421410.001]
  • [Cites] Nat Med. 1997 Aug;3(8):908-12 [9256284.001]
  • [Cites] Hum Pathol. 1977 Jan;8(1):83-94 [844856.001]
  • [Cites] Swiss Surg. 2003;9(6):311-4 [14725101.001]
  • [Cites] Zentralbl Chir. 2001 Mar;126(3):229-32 [11301890.001]
  • [Cites] Adv Anat Pathol. 2006 Jan;13(1):16-25 [16462153.001]
  • [Cites] Histopathology. 2009 Jan;54(1):55-68 [19054156.001]
  • [Cites] Cancer. 1998 Dec 15;83(12):2437-46 [9874447.001]
  • [Cites] Am J Surg Pathol. 2000 Sep;24(9):1183-200 [10976692.001]
  • [Cites] Histopathology. 2002 Mar;40(3):237-44 [11895489.001]
  • [Cites] J Occup Environ Med. 2003 Apr;45(4):451-5 [12708149.001]
  • [Cites] Am J Epidemiol. 2004 Jan 15;159(2):107-12 [14718210.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1379-85 [8608519.001]
  • [Cites] Pathologe. 1989 Mar;10(2):114-7 [2717537.001]
  • [Cites] Arch Pathol Lab Med. 2007 Jan;131(1):138-44 [17227115.001]
  • [Cites] Curr Opin Pulm Med. 1999 Sep;5(5):326-31 [10461539.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2009 Apr 24;58(15):393-6 [19390506.001]
  • [Cites] Gynecol Oncol. 2005 Jul;98(1):161-7 [15894368.001]
  • [Cites] Int J Cancer. 1987 Jan 15;39(1):10-7 [3025107.001]
  • [Cites] J Surg Oncol. 2008 Sep 15;98(4):268-72 [18726890.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):243-51 [11920782.001]
  • [Cites] Occup Environ Med. 1994 Dec;51(12):804-11 [7849863.001]
  • [Cites] Cancer. 1989 Sep 15;64(6):1336-46 [2766227.001]
  • [Cites] Am J Pathol. 1981 Mar;102(3):314-23 [7212016.001]
  • [Cites] Int Arch Occup Environ Health. 2001 Aug;74(6):383-95 [11563601.001]
  • [Cites] Cancer. 1975 Oct;36(4):1381-5 [1175135.001]
  • [Cites] Soz Praventivmed. 1982 Oct;27(5):220-2 [7158050.001]
  • [Cites] Occup Environ Med. 2007 Dec;64(12):839-42 [17567726.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(5):443-7 [2122588.001]
  • [Cites] Cancer Sci. 2006 Apr;97(4):292-5 [16630121.001]
  • [Cites] Chest. 1993 Apr;103(4 Suppl):373S-376S [8462328.001]
  • [Cites] Am J Surg Pathol. 1992 May;16(5):467-75 [1599025.001]
  • [Cites] Thorax. 1997 Jun;52(6):507-12 [9227715.001]
  • [Cites] World J Surg. 2006 Apr;30(4):560-6 [16547615.001]
  • [Cites] Chirurg. 2000 Aug;71(8):877-86 [11013806.001]
  • [Cites] Aktuelle Urol. 2006 Jul;37(4):281-3 [16878282.001]
  • [Cites] Am J Surg Pathol. 2008 Nov;32(11):1627-42 [18753943.001]
  • [Cites] Br J Dis Chest. 1983 Oct;77(4):321-43 [6357260.001]
  • [Cites] Adv Anat Pathol. 2009 Jan;16(1):62-4 [19098468.001]
  • [Cites] Environ Health Perspect. 1983 Nov;53:121-30 [6662082.001]
  • (PMID = 19856150.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 76
  •  go-up   go-down


89. Afify AM, Stern R, Michael CW: Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization. Diagn Cytopathol; 2005 Mar;32(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All MMs and 93% (26/28) of the benign mesothelial cells were positive for intracytoplasmic HA vs. none of ACAs.
  • CD44 may prove useful in conjunction with other stains in the differential diagnosis of mesothelioma and ADA.
  • [MeSH-major] Adenocarcinoma / diagnosis. Antigens, CD44 / metabolism. Ascitic Fluid / metabolism. Hyaluronic Acid / metabolism. Mesothelioma / diagnosis. Pleural Effusion, Malignant / metabolism
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Neoplasm Metastasis. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HYALURONIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Wiley-Liss, Inc.
  • (PMID = 15690337.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44S antigen; 9004-61-9 / Hyaluronic Acid
  •  go-up   go-down


90. Zendehrokh N, Rehnberg J, Dejmek A: Comparison of NCL-hTERT antibody reactivity and telomere repeat amplification protocol in situ in effusions. Acta Cytol; 2007 Nov-Dec;51(6):886-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results were compared and correlated to diagnosis.
  • Twenty effusions, all containing mesothelial cells, came from patients with benign conditions.
  • Thus the results of TRAP in situ and hTERT immunohistochemistry disagreed in 1 of 34 (3%) malignant and 12 of 20 (60%) benign cases.
  • [MeSH-major] Ascitic Fluid / enzymology. Immunohistochemistry / methods. Pleural Effusion / enzymology. Polymerase Chain Reaction / methods. Telomerase / metabolism. Telomere / enzymology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Cell Nucleus / enzymology. Cell Nucleus / genetics. DNA, Neoplasm / analysis. Female. Humans. Neoplasms, Mesothelial / diagnosis. Neoplasms, Mesothelial / enzymology. Phosphoproteins / immunology. Phosphoproteins / metabolism. RNA-Binding Proteins / immunology. RNA-Binding Proteins / metabolism. Repetitive Sequences, Nucleic Acid / genetics. Reproducibility of Results. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18077981.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Phosphoproteins; 0 / RNA-Binding Proteins; 0 / nucleolin; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


91. Song SW, Jung JI, Lee KY, Kim MY, Park SH: Malignant solitary fibrous tumor of the pleura: computed tomography-pathological correlation and comparison with computed tomography of benign solitary fibrous tumor of the pleura. Jpn J Radiol; 2010 Oct;28(8):602-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant solitary fibrous tumor of the pleura: computed tomography-pathological correlation and comparison with computed tomography of benign solitary fibrous tumor of the pleura.
  • PURPOSE: The aim of this study was to determine the computed tomography (CT)-pathological correlation of malignant solitary fibrous tumors of the pleura (MSFP) and to compare these findings with CT findings of benign solitary fibrous tumors of the pleura (BSFTP).
  • Pleural metastasis (57.1%) and lung metastasis (14.3%) were associated.
  • MSFPs showed a higher incidence of intratumoral low-attenuation areas (P = 0.034) and pleural metastasis (P = 0.009); and on CT, MSFPs tended to be larger than BSFTPs (P = 0.076).
  • CONCLUSION: MSFPs showed a >10 cm pleural mass with low-attenuation regions on CT, which corresponded to hemorrhage, necrosis, cystic, or myxoid degeneration.
  • MSFPs had a higher incidence of intratumoral low-attenuation areas and pleural metastasis, and on CT they tended to be larger than BSFTPs.
  • [MeSH-major] Solitary Fibrous Tumor, Pleural / diagnostic imaging. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Clin Imaging. 1991 Apr-Jun;15(2):105-8 [1913308.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):440-9 [7705824.001]
  • [Cites] Eur J Radiol. 2000 May;34(2):98-118 [10874176.001]
  • [Cites] Radiographics. 2003 May-Jun;23(3):759-83 [12740474.001]
  • [Cites] J Comput Assist Tomogr. 1997 Jan-Feb;21(1):115-20 [9022782.001]
  • [Cites] AJR Am J Roentgenol. 1992 May;158(5):983-6 [1566702.001]
  • [Cites] J Thorac Imaging. 1998 Jan;13(1):27-35 [9440836.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • [Cites] Clin Radiol. 1992 Jan;45(1):13-7 [1740027.001]
  • [Cites] Cancer. 2002 Feb 15;94(4):1057-68 [11920476.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] AJR Am J Roentgenol. 1997 Sep;169(3):683-6 [9275877.001]
  • (PMID = 20972860.001).
  • [ISSN] 1867-108X
  • [Journal-full-title] Japanese journal of radiology
  • [ISO-abbreviation] Jpn J Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


92. Santos RS, Haddad R, Lima CE, Liu YL, Misztal M, Ferreira T, Boasquevisque CH, Luketich JD, Landreneau RJ: Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura. Clin Lung Cancer; 2005 Nov;7(3):197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patterns of recurrence and long-term survival after curative resection of localized fibrous tumors of the pleura.
  • BACKGROUND: Localized fibrous tumors of the pleura (LFTPs) are uncommon thoracic neoplasms with variable malignant potential that were previously classified as benign presentation of mesothelioma.
  • The malignant potential of the tumor was estimated through histologic assessment of the degree of cellularity, mitotic activity, and nuclear pleomorphism.
  • Ipsilateral pleural recurrence remote to the original tumor site occurred in 6 of these patients with malignant microscopic characteristics at a mean of 9 months after resection.
  • There have been no recurrences among the other 27 patients with benign histologic features, and 31 patients remain alive at a median follow-up of 34.5 months.
  • [MeSH-major] Neoplasm Recurrence, Local. Neoplasms, Fibrous Tissue / surgery. Pleura / surgery. Pleural Neoplasms / surgery

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354315.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Inaoka T, Takahashi K, Miyokawa N, Ohsaki Y, Aburano T: Solitary fibrous tumor of the pleura: apparent diffusion coefficient (ADC) value and ADC map to predict malignant transformation. J Magn Reson Imaging; 2007 Jul;26(1):155-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura: apparent diffusion coefficient (ADC) value and ADC map to predict malignant transformation.
  • Solitary fibrous tumors (SFTs) of the pleura are rare soft-tissue tumors that are presumed to be of mesenchymal origin.
  • Most SFTs are histologically benign, but up to 20% of SFTs may be malignant.
  • In addition, malignant transformation may occur within histologically benign SFTs, though it is rare.
  • However, it is difficult to diagnose malignant SFTs of the pleura by means of conventional computed tomography and magnetic resonance imaging (MRI).
  • In this article we present the first case of malignant SFT of the pleura in an 81-year-old man in which the apparent diffusion coefficient (ADC) value and ADC map based on diffusion-weighted MRI were very useful for identifying malignant transformation.
  • [MeSH-major] Diffusion Magnetic Resonance Imaging. Fibroma / diagnosis. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Cell Transformation, Neoplastic. Contrast Media. Diagnosis, Differential. Humans. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Wiley-Liss, Inc.
  • (PMID = 17659560.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


94. Rodríguez-Piñeiro AM, Blanco-Prieto S, Sánchez-Otero N, Rodríguez-Berrocal FJ, de la Cadena MP: On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics; 2010 Jun 16;73(8):1511-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion.
  • The current imperative need for new biomarkers of non-small cell lung cancer (NSCLC) prompted us to compare the proteome of serum and pleural effusion samples from cancer patients with those with benign lung diseases as pneumonia or tuberculosis.
  • Overall, we identified more potential biomarkers in pleural effusion, which is closer to the affected organ, than in serum.
  • The biomarker candidates comprise proteins increased in malignant pleural effusions as gelsolin and the metalloproteinase inhibitor 2, and others with lower levels as S100-A8 and S100-A9.
  • The most interesting protein was the pigment epithelium-derived factor (PEDF), which is related to angiogenesis inhibition, and was significantly overexpressed both in serum and pleural effusion from NSCLC patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / chemistry. Lung Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Electrophoresis, Gel, Two-Dimensional. Eye Proteins / analysis. Female. Humans. Male. Middle Aged. Nerve Growth Factors / analysis. Pleural Effusion / metabolism. Pleural Effusion, Malignant / metabolism. Pneumonia / metabolism. Protein Isoforms / analysis. Proteomics / methods. Serpins / analysis. Tuberculosis, Pulmonary / metabolism


95. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Grégoire M, Porte H, Copin MC, Lassalle P: Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res; 2007 May 15;13(10):2928-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
  • PURPOSE: Malignant mesothelioma is a highly aggressive tumor and is often diagnosed too late for a curative treatment.
  • We compared diagnostic and prognostic values of mesothelin and osteopontin in 172 patients suspected of malignant pleural mesothelioma (MPM) and in a control group of 112 asymptomatic asbestos-exposed subjects.
  • EXPERIMENTAL DESIGN: Osteopontin and mesothelin were assayed with commercial ELISA kits in a series of 43 patients with pleural metastases of various carcinomas, 33 patients with benign pleural lesions associated with asbestos exposure, 96 patients with MPMs, and 112 asbestos-exposed healthy subjects.
  • Results were correlated with patient's diagnosis and survival.
  • However, osteopontin was unable to distinguish between MPM and pleural metastatic carcinoma or benign pleural lesions associated with asbestos exposure.
  • Neither plasma nor pleural fluid osteopontin were more powerful in this respect.
  • Survival analysis identified tumor histologic subtype along with serum osteopontin and serum mesothelin as independent prognostic factors in mesothelioma patients.
  • [MeSH-major] Membrane Glycoproteins / blood. Mesothelioma / diagnosis. Osteopontin / blood. Pleural Neoplasms / diagnosis
  • [MeSH-minor] Aged. Extracellular Fluid / chemistry. Female. GPI-Linked Proteins. Humans. Male. Middle Aged. Pleura / chemistry. Prognosis. Survival Analysis

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504993.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GPI-Linked Proteins; 0 / Membrane Glycoproteins; 0 / mesothelin; 106441-73-0 / Osteopontin
  •  go-up   go-down


96. Wang W, Quan CB, Li N, Wang XJ, Song JY, Jia SL, Lin MG: [Diagnosis of pleural cavity extraskeletal osteosarcoma: a case report and literature review]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Mar;33(3):202-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of pleural cavity extraskeletal osteosarcoma: a case report and literature review].
  • OBJECTIVE: To describe the manifestations and diagnosis of pleural cavity extraskeletal osteosarcoma (ESO).
  • RESULTS: Chest CT of a middle-aged man revealed an enormous heterogeneous neoplasm, about 10.9 cm x 9.2 cm x 17.7 cm in size, in the left pleural cavity.
  • There was abundant calcification in the tumor, with signs of invasion into the diaphragm and the pleura.
  • Pleural effusion of the left thoracic cavity was also seen on the chest CT.
  • Osteosarcoma was confirmed by pathological study after surgical resection of the tumor.
  • Pleural cavity ESO is insidious and imaging studies often reveal a huge mass with abundant calcification.
  • The differential diagnosis includes benign and malignant diseases of the thorax.
  • [MeSH-major] Osteosarcoma. Pleural Cavity / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450640.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


97. Ouadnouni Y, Bouchikh M, Bekarsabein S, Achir A, Smahi M, Msougar Y, Mahassini N, Benosman A: Endobronchial lipoma a rare cause of pleural empyema: a case report. Cases J; 2009;2:6377
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endobronchial lipoma a rare cause of pleural empyema: a case report.
  • Benign neoplasm of the endobronchial tree is quite rare, while endobronchial lipoma is extremely rare.
  • The irreversible pulmonary damage is due to progressive bronchial obstruction; even so, pleural empyema is exceptionally encountered in a case of endobronchial lipoma.
  • The chest computed tomography showed cystic bronchiectasis with pleural effusion, Flexible bronchoscopy revealed a round tumor on the left main bronchus.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Bronconeumol. 2005 Mar;41(3):172-4 [15766470.001]
  • [Cites] Neth J Med. 1997 Oct;51(4):143-5 [9446925.001]
  • [Cites] Chest. 2003 Jan;123(1):293-6 [12527636.001]
  • [Cites] Nouv Presse Med. 1981 Jan 24;10(3):177 [7220324.001]
  • [Cites] Rofo. 1982 May;136(5):595-6 [6212510.001]
  • (PMID = 19829798.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2740244
  •  go-up   go-down


98. Bayod MJ, Carlón ME, Idoate MA: [Pseudomeigs syndrome in a patient with Krukenberg's tumor]. Rev Med Univ Navarra; 2007 Jul-Sep;51(3):19-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pseudomeigs syndrome in a patient with Krukenberg's tumor].
  • [Transliterated title] Síndrome de Pseudomeigs en paciente con tumor de Krukenberg.
  • She came to our institution with a twenty month history of dysnea secondary to pleural effussion, bilateral lower extremity edema and probably had ascitis.
  • The anatomopathological analysis showed bilateral ovarian implants from signet ring cell adenocarcinoma (Krukenberg tumor).
  • This patient developed a PseudoMeigs syndrome consisting on malignant ovarian tumor asociated with ascitis and pleural effusion without malignant cells.
  • Oncological patients who present with ascitis and benign pleural effusion, the diagnosis of PseudoMeigs syndrome should be considered.
  • [MeSH-major] Carcinoma, Signet Ring Cell / secondary. Krukenberg Tumor / diagnosis. Meigs Syndrome / diagnosis. Neoplasms, Multiple Primary. Ovarian Neoplasms / secondary. Stomach Neoplasms / pathology
  • [MeSH-minor] Ascites / etiology. Diagnosis, Differential. Diagnostic Imaging. Female. Fibroma / diagnosis. Humans. Lymphoma, Follicular. Middle Aged. Pleural Effusion / etiology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18183782.001).
  • [ISSN] 0556-6177
  • [Journal-full-title] Revista de medicina de la Universidad de Navarra
  • [ISO-abbreviation] Rev Med Univ Navarra
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


99. Sethuraman C, Simmerson M, Vora AJ, Cohen MC: Flowcytometric immunophenotyping in the diagnosis of pediatric lymphoma: how reliable is it and how can we optimize its use? J Pediatr Hematol Oncol; 2010 May;32(4):298-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flowcytometric immunophenotyping in the diagnosis of pediatric lymphoma: how reliable is it and how can we optimize its use?
  • We conducted a retrospective review of 39 fresh tissue samples and 2 pleural fluids submitted to the histopathology department with a clinical suspicion of lymphoma during a 4-year period, where FCI was performed.
  • The FCI results were correlated with the final histologic diagnosis.
  • In one of them, FCI supported the diagnosis of neuroblastoma when CD81, CD9, GD2, and CD56 were added to the FCI panel.
  • FCI produced rapid same-day results with a high sensitivity for benign lymphoid lesions and non-Hodgkin lymphoma.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Neuroblastoma / diagnosis
  • [MeSH-minor] Adult. Algorithms. Biomarkers, Tumor / metabolism. Flow Cytometry. Humans. Immunoenzyme Techniques. Immunophenotyping. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20224437.001).
  • [ISSN] 1536-3678
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0300130
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


100. Cheng M, Chen Y, Yu X, Tian Z, Wei H: Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer. BMC Cancer; 2008;8:156
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic utility of LunX mRNA in peripheral blood and pleural fluid in patients with primary non-small cell lung cancer.
  • The goal of this study was to provide a detailed evaluation of lung cancer tumor markers indicative of molecular abnormalities and to assess their diagnostic utility in non-small cell lung cancer (NSCLC) patients.
  • METHODS: Quantitative real-time RT-PCR was used to determine LunX, CK19, CEA, VEGF-C and hnRNP A2/B1 mRNA levels in peripheral blood and pleural fluid from NSCLC patients, compared with those from patients with other epithelial cancer (esophagus cancer and breast cancer), benign lung disease (pneumonia and tuberculo pleurisy) and from healthy volunteers.
  • RESULTS: In peripheral blood LunX mRNA was detectable in 75.0% (33/44) of patients with NSCLC, but not in patients with other epithelial cancer (0/28), benign lung disease (0/10) or in healthy volunteers (0/15).
  • In contrast, all other genetic markers were detected in patients with either NSCLC, other epithelia cancer or benign lung disease, and in healthy volunteers.
  • Furthermore, LunX mRNA was detected in 92.9% (13/14) of malignant pleural fluid samples and was the only marker whose expression level was significantly different between malignant and benign pleural fluid (P < 0.001).
  • CONCLUSION: Of several commonly used genetic markers, LunX mRNA is the most specific gene marker for lung cancer and has potential diagnostic utility when measured in the peripheral blood and pleural fluid of NSCLC patients.
  • [MeSH-major] Biomarkers, Tumor. Carcinoma, Non-Small-Cell Lung / diagnosis. Glycoproteins / genetics. Lung Neoplasms / diagnosis. Phosphoproteins / genetics
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Pleural Effusion, Malignant / genetics. RNA, Messenger / blood

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 2002 Mar;123(3):484-91; discussion 491 [11882819.001]
  • [Cites] Proteomics. 2002 Jan;2(1):112-20 [11788998.001]
  • [Cites] J Pathol. 2003 May;200(1):88-94 [12692846.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):611-8 [12845661.001]
  • [Cites] J Pathol. 2003 Jul;200(3):336-47 [12845630.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3694-9 [12915657.001]
  • [Cites] J Mol Diagn. 2003 Nov;5(4):237-42 [14573783.001]
  • [Cites] Curr Opin Pulm Med. 2004 Jul;10(4):242-7 [15220746.001]
  • [Cites] Mod Pathol. 1991 May;4(3):320-4 [2068057.001]
  • [Cites] J Clin Oncol. 1994 Mar;12(3):475-82 [7509852.001]
  • [Cites] J Thorac Cardiovasc Surg. 1995 Jan;109(1):120-9 [7815787.001]
  • [Cites] Am J Surg. 1995 Jul;170(1):69-74 [7793501.001]
  • [Cites] Chest. 1995 Jul;108(1):163-9 [7541742.001]
  • [Cites] Chest. 1997 Jun;111(6):1718-23 [9187199.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3388-93 [9363870.001]
  • [Cites] Cancer. 1998 Apr 15;82(8):1419-42 [9554517.001]
  • [Cites] Int J Cancer. 1998 Nov 23;78(5):661-6 [9808539.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1113-24 [10393719.001]
  • [Cites] Eur J Cancer. 2005 Jan;41(2):306-12 [15661557.001]
  • [Cites] Chest. 2005 Feb;127(2):430-7 [15705978.001]
  • [Cites] Chest. 2005 Sep;128(3):1539-44 [16162755.001]
  • [Cites] Chest. 2005 Oct;128(4):2298-303 [16236887.001]
  • [Cites] Neoplasia. 2005 Dec;7(12):1073-80 [16354590.001]
  • [Cites] In Vivo. 2000 Jan-Feb;14(1):237-50 [10757082.001]
  • [Cites] J Mol Endocrinol. 2000 Oct;25(2):169-93 [11013345.001]
  • [Cites] Int J Cancer. 2001 Feb 15;91(4):433-7 [11251963.001]
  • [Cites] Electrophoresis. 2001 May;22(9):1795-800 [11425234.001]
  • [Cites] Int J Cancer. 2002 Aug 10;100(5):592-9 [12124810.001]
  • (PMID = 18513434.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BPIFA1 protein, human; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Phosphoproteins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC2424066
  •  go-up   go-down






Advertisement